

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Richard A. Adams, MD¹; David J. Fisher, MSc²; Janet Graham, MD³; Jenny F. Seligmann, PhD⁴; Matthew Seymour, PhD⁴;
Richard Kaplan, MD, PhD²; Emma Yates, MSc²; Mahesh Parmar, PhD²; Susan D. Richman, PhD⁴; Philip Quirke, PhD⁴;
Rachel Butler, PhD⁵; Ewan Brown, MD⁶; Fiona Collinson, MD⁴; Stephen Falk, MD⁷; Harpreet Wasan, PhD⁸; Kai-Keen Shiu, PhD⁹;
Gary Middleton, PhD¹⁰; Leslie Samuel, MD¹¹; Richard H. Wilson, PhD³; Louise C. Brown, PhD²; and Timothy S. Maughan, MD¹²
on behalf of the FOCUS4 Trial Investigators

PURPOSE Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (OS). FOCUS4-N was set up to explore the impact of oral maintenance therapy in patients who are responding to first-line therapy.

METHODS FOCUS4 was a molecularly stratified trial program that registered patients with newly diagnosed mCRC. The FOCUS4-N trial was offered to patients in whom a targeted subtrial was unavailable or biomarker tests failed. Patients were randomly assigned using a 1:1 ratio between maintenance capecitabine and active monitoring (AM). The primary outcome was progression-free survival (PFS) with secondary outcomes including OS toxicity and tolerability.

RESULTS Between March 2014 and March 2020, 254 patients were randomly assigned (127 to capecitabine and 127 to AM) across 88 UK sites. Baseline characteristics were balanced. There was strong evidence of efficacy for PFS (hazard ratio = 0.40; 95% Cl, 0.21 to 0.75; P < .0001), but no significant improvement in OS (hazard ratio, 0.93; 95% Cl, 0.69 to 1.27; P = .66) was observed. Compliance with treatment was good, and toxicity from capecitabine versus AM was as expected with grade ≥ 2 fatigue (25% v 12%), diarrhea (23% v 13%), and hand-foot syndrome (26% v 3%). Quality of life showed little difference between the groups.

CONCLUSION Despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients who are stable or responding to first-line treatment for mCRC. Capecitabine without bevacizumab may be used to extend PFS in the interval after 16 weeks of first-line therapy.

J Clin Oncol 39:3693-3704. © 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License 🞯 🌖

INTRODUCTION

Treatment breaks in patients receiving palliative chemotherapy for metastatic colorectal cancer (mCRC) reduce toxicity burden and improve quality of life (QoL).¹ However, current standards either mandate or recommend a strategy of continuing therapy, until progression or excess toxicity. Standard maintenance strategies in high-income countries favor combined oral capecitabine with intravenous bevacizumab once every 3 weeks,^{2,3} on the basis of the phase III CAIRO3⁴ and AIO-0207⁵ studies. Health economic evaluation of this approach has previously indicated a lack of cost-effectiveness driven by nonsignificant improvement in overall survival (OS) and high costs of intravenous

bevacizumab (drug plus administration).⁶ Previous studies have evaluated a range of strategies to either completely stop therapy as a treatment holiday, reducing toxicities and hospital visits, or attenuate therapy, removing certain drugs as a maintenance therapy in comparison with historic standard-of-care continuation of maximum tolerated dose of treatment. Meta-analysis of these approaches overall shows no difference in OS.⁷ Notably, maintenance strategies, almost uniformly, demonstrate an improvement in progression-free survival (PFS), but at the expense of ongoing (though attenuated) toxicity and unending multiple hospital visits for intravenous therapy. In the FOCUS4-N trial (embedded within the FOCUS4 trial

CONTENT See accompanying editorial on page 3656 Appendix

ASSOCIATED

Data Supplement Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on August 16, 2021 and published at ascopubs.org/journal/ jco on September 13, 2021: DOI https://doi. org/10.1200/JC0.21. 01436



CONTEXT

Key Objective

In patients with metastatic colorectal cancer, first-line systemic anticancer therapy (SACT) with palliative intent aims to extend overall survival (OS) while maintaining quality of life. Current guidelines recommend a maintenance strategy of oral capecitabine and bevacizumab in patients with disease control after 4-6 months of induction SACT. This is based upon improved progression-free survival (without evidence of OS benefit) compared with a complete treatment break with active monitoring (AM). FOCUS4-N aims to establish the impact of maintenance capecitabine monotherapy versus AM.

Knowledge Generated

These results demonstrate that capecitabine can double the time until return to induction SACT. However, patients may adopt an AM approach without detriment in OS and with less toxicity.

Relevance

FOCUS4-N provides information for patients and clinicians, which will assist decision making at the end of induction SACT. Capecitabine without intravenous bevacizumab is likely more cost-effective than the current recommended approach of capecitabine and bevacizumab.

program, see the Data Supplement [online only]), we have explored the oral strategy of capecitabine only versus active monitoring (AM). This will allow us to study the potential impact on PFS, toxicity, and QoL, which will enable patients and clinicians to choose an optimum approach tailored to the individual.

The FOCUS4 trial program is a molecularly stratified umbrella platform trial (Data Supplement) that evaluated safety and efficacy of novel treatments in targeted biomarker subgroups within a phase II or III trial setting. The trial used adaptive statistical methodology that allowed the addition of new therapies and the dropping of ineffective ones and including a nonstratified comparison (FOCUS4-N) for patients in whom a molecularly stratified comparison was unavailable or the biomarker tests failed for their tumor tissue. In the Data Supplement, we describe the design and methods for patient registration and biomarker testing. In this article, we report the findings of FOCUS4-N, which tested the efficacy of capecitabine as a maintenance therapy versus AM in patients with mCRC.

METHODS

Trial Approvals, Patient Eligibility, and Recruitment

The trial and subsequent amendments were approved by the UK National Ethics Committee Oxford (reference 13/SC/ 0111) and by the relevant regulatory body MHRA (CTA# 20363/0400/001 and EudraCT# 2012-005111-12).

Patients age at least 18 years with newly diagnosed locally advanced or mCRC were eligible for registration in the FOCUS4 trial program (see the Data Supplement for details of FOCUS4 design and registration methods). Patients whose tumors had remained stable or responded to treatment according to their 16-week computed tomography (CT) were assessed for eligibility for the FOCUS4-N

comparison. In addition to the registration eligibility criteria, patients were required to have a baseline randomly assigned CT scan performed within 4 weeks prerandomization; a minimum 3-week washout period between the last chemotherapy or biologic therapy dose and the first capecitabine dose; adequate renal (creatinine clearance > 50 mL/min) and liver function; and a WHO performance status of 0-2. Patients who were eligible for either FOCUS4-N or a molecularly stratified trial were offered entry into either and given the option of which study to participate in, followed by appropriate consent.

In the first phase of FOCUS4 between January 2014 and June 2017, patients with raised baseline platelet count (thrombocytosis) were considered ineligible on the basis of previous data from the COIN trial (which indicated a significant survival detriment in this patient group receiving an intermittent strategy).¹ A subsequent individual patient data meta-analysis of phase II or III intermittent strategy trials did not confirm the observation from COIN.⁸ Thus, between June 2017 and March 2020, eligibility criteria were adapted, allowing inclusion of this patient group with thrombocytosis.

Trial Procedures

Patients randomly assigned to capecitabine were asked to continue taking the drug until disease progression, death, or intolerable toxicity. Capecitabine was dosed according to standard guidelines, orally twice daily for 14 days followed by a 7-day rest period without capecitabine tablets.

Patient tumor status was assessed every 8 weeks by CT scan reviewed at the treating hospital site according to RECIST version 1.1.⁹ Toxicities and symptoms were assessed locally every 4 weeks from random assignment or start of treatment using NCI CTCAE (version 3.0). Patients were followed until progressive disease, at which point the

patient was recommended to restart first-line systemic therapy.

Treatment was stopped for grade ≥ 3 toxic effects or persistent toxicities judged medically important or not tolerated by the patient, until the toxicity resolved to grade 1 or better. After stopping treatment, capecitabine could be reinitiated at a reduced dose. Any stoppage for ≥ 28 days was not permitted, with the patient discontinued from trial therapy but remaining under follow-up.

QoL data using EQ-5D were collected at random assignment, every 8 (7-9) weeks until progression, 4 weeks after end of trial treatment, 3 months after progression, and then every 6 months.

Statistical Methods

Treatment allocation. Patients were allocated to capecitabine or AM by a centrally managed telephone service at the MRC Clinical Trials Unit at University College London, using a 1:1 allocation ratio by minimization with a random element of 20%. Minimization factors were treating hospital site, primary tumor site (right colon, left colon, or rectum), WHO performance status (0, 1, or 2), 16-week CT scan result (stable disease and partial or complete response), number of metastatic sites (none, one, or two or more), and first-line therapy regimen (fluorouracil, capecitabine, or neither; both oxaliplatin and irinotecan, irinotecan only, or neither; and cetuximab or panitumumab, bevacizumab, or no monoclonal antibody).

Outcome measures. The primary FOCUS4-N outcome was PFS, defined as time from random assignment to either disease progression (according to RECIST criteria) or death from any cause. Patients without a PFS event were censored at the time of their last recorded CT scan. OS was a secondary outcome, defined as time from random assignment to death from any cause with patients censored at last recorded disease assessment, blood measurement, or anticancer treatment. Other secondary outcomes included safety, toxicity, QoL, and tumor response. QoL was analyzed using mixed-effects linear modeling with patient-level random intercepts and time slopes, with differences by the treatment arm tested by evaluating the area under the curve from the model.

Sample size calculation. The FOCUS4-N target sample size was calculated using the Analysis of Resources for Trials program implemented in Stata software. Given that the recruitment rate into FOCUS4-N was dependent on the availability of other molecular comparisons, failure of biomarker testing, or patient choice, exact recruitment figures were unknown at the trial commencement. Various scenarios were used to estimate the recruitment rate over 5 years, and we assumed a 4-month median PFS in the AM arm (on the basis of COIN trial data). A total of 644 patients (635 events) would provide 80% power of detecting a hazard ratio (HR) of 0.8 at the two-sided 5% significance level.

In March 2020, the COVID-19 pandemic resulted in temporary closure of FOCUS4 to new recruitment. Following Independent Data Monitoring Committee review and recommendation, a decision was taken to close recruitment permanently in April 2020 as trial funding was nearing its end. A previous review of the implications of reduced recruitment on the statistical power of FOCUS4-N had been considered by our funders who recommended that, despite reduced power, the trial should close in 2020 and report the data accrued up to that point. Furthermore, at analysis, it became clear that the observed HR was substantially more extreme than the target HR on which we based our original sample size.

Statistical analysis. All analyses were performed according to a predefined statistical analysis plan agreed before database lock. We analyzed using Stata statistical software, version 16.1 (Stata Corporation, TX). The primary analysis was performed according to intention-to-treat with a secondary per-protocol analysis defined by patients who completed at least one cycle of trial treatment (\geq 28 days). Patients were censored according to the following criteria. For survival status, we censored patients on the date that they were last known to be alive, either via collection of prescription from their hospital pharmacy or attendance at a follow-up visit or CT scan. For PFS, we censored patients without progression on the date of the last CT scan showing no progression. For patients who died before any follow-up visit or CT scan, we used the date of death as the date of the event and assumed death without progression, provided that the death occurred within 3 months of random assignment or any previous scan confirming no progression.

Kaplan-Meier curves were used to present survival data and Cox regression modeling to estimate HRs between randomized groups. Unadjusted HRs and the ones adjusted for the stratification factors used to minimize patients into allocated groups (primary analysis) were estimated. A further analysis also adjusted for resection status, timing of metastatic disease, alkaline phosphatase, white blood cell count, age of tumor sample, and use of aspirin at baseline. Deviation from nonproportional hazards was assessed using regression of scaled Schoenfeld residuals against the log of time.

RESULTS

Recruitment and Compliance

Across 88 UK hospitals, between January 2014 and March 2020, 1,434 patients were registered into FOCUS4, of whom 924 underwent successful biomarker assessment and completed 16 weeks of first-line therapy with either stable or responding disease (Data Supplement). Of these patients, 254 were randomly assigned to FOCUS4-N (Fig 1), 127 to AM and 127 to maintenance capecitabine.

Adams et al




FIG 1. Flow diagram showing patient flow through the FOCUS4-N trial. CR, complete response; PR, partial response; SD, stable disease.

Baseline demographic and clinical characteristics were well-balanced between the study arms (Table 1 and Appendix Table A1, online only). Most patients had widespread synchronous metastatic disease with about half having an unresected primary tumor. A right-sided primary

tumor location was present in about one third. The majority were treated with doublet chemotherapy (irinotecan-based 57%) without a monoclonal antibody (as bevacizumab is not reimbursed in the United Kingdom). The Data Supplement shows induction chemotherapy for all patients

TABLE 1. Baseline Characteristics for Characteristic	FOCUS4-N Active Monitoring (n = 127)	Capecitabine (n = 127)
Mean (SD) age, years	63.7 (10.9)	64.7 (9.6)
Sex, No. (%)		
Male	76 (60)	86 (68)
Female	51 (40)	41 (32)
Baseline WHO performance status, No. (%)		
0	76 (60)	80 (63)
1	49 (39)	45 (35)
2	2 (2)	2 (2)
Site of primary tumor, No. (%)		
Right colon	45 (35)	47 (37)
Left colon	32 (25)	33 (26)
Rectum	50 (39)	47 (37)
Current state of primary tumor, No. (%)		
Resected primary	62 (49)	54 (43)
Unresected primary	61 (48)	68 (54)
Unresected local recurrence	4 (3)	5 (4)
No. of metastatic sites, No. (%)		
No metastases	2 (2)	4 (3)
One	41 (32)	40 (31)
Two or more	84 (66)	83 (65)
Timing of metastases, No. (%)		
Metachronous	40 (31)	21 (17)
Synchronous	85 (67)	101 (80)
No metastases	2 (2)	4 (3)
Missing data	0 (0)	1 (1)
Disease assessment at end of first- line treatment, No. (%)		
Complete response	3 (2)	5 (4)
Partial response	75 (59)	71 (56)
Stable disease	49 (39)	51 (40)
Fluoropyrimidine drug used during first-line treatment, No. (%)		
FU	95 (75)	97 (76)
Capecitabine	32 (25)	30 (24)
Oxaliplatin or irinotecan used during first-line treatment, No. (%)		
Both oxaliplatin and irinotecan	2 (2)	2 (2)
Oxaliplatin only	50 (39)	50 (39)
Irinotecan only	73 (57)	71 (56)
Neither	2 (2)	4 (3)
Monoclonal antibody used during first-line treatment, No. (%)		
(continued in nex	t column)	

TABLE 1. Baseline Characteristics for	-	continued)
Characteristic	Active Monitoring (n = 127)	Capecitabine (n = 127)
Cetuximab/panitumumab	25 (20)	20 (16)
Bevacizumab	6 (5)	7 (6)
No antibody	96 (76)	100 (79)
PIK3CA mutation status, No. (%)		
Mutation	15 (12)	14 (11)
Wild type	96 (76)	100 (79)
Failed	7 (6)	5 (4)
Insufficient tumor	9 (7)	8 (6)
BRAF mutation status, No. (%)		
Mutation	13 (10)	17 (13)
Wild type	103 (81)	98 (77)
Failed	2 (2)	4 (3)
Insufficient tumor	9 (7)	8 (6)
RAS mutation status, No. (%)		
Mutation	68 (54)	68 (54)
Wild type	47 (37)	48 (38)
Failed	3 (2)	3 (2)
Insufficient tumor	9 (7)	8 (6)
TP53 mutation status, No. (%)		
Mutation	61 (48)	62 (49)
Wild type	33 (26)	28 (22)
Failed	3 (2)	2 (2)
Could not be tested	18 (14)	24 (19)
Insufficient tumor	12 (9)	11 (9)
MSI status, No. (%)		
MSS	108 (85)	104 (82)
MSI	2 (2)	3 (2)
Failed	2 (2)	4 (3)
Could not be tested	6 (5)	8 (6)
Insufficient tumor	9 (7)	8 (6)
Total	127 (100)	127 (100)

Abbreviations: FU, fluorouracil; MSI, microsatellite instable; MSS, microsatellite stable; SD, standard deviation.

in FOCUS4, and the Data Supplement shows disease response to induction chemotherapy on the basis of biomarker subgroup. The molecular characteristics are shown in Table 1 (and the Data Supplement for all FOCUS4 participants), showing that only 37% had an *RAS* wildtype tumor reflecting NHS England policy of not allowing treatment breaks for patients on epidermal growth factor receptor monoclonal antibodies.

Compliance with randomized allocation was good with only one patient in the AM arm receiving capecitabine approximately 6 months before progression. Patients in Adams et al




FIG 2. Kaplan-Meier curve for PFS in FOCUS4-N. Cox regression HR, adjusted for minimization factors = 0.40 (95% CI, 0.21 to 0.75), P < .0001. Minimization factors: location of primary tumor (left, right, and rectum), baseline WHO performance status, baseline disease assessment, No. of metastases, first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody), and biomarker cohort, stratified for FO-CUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; PFS, progression-free survival.

the capecitabine arm received a median of four cycles (interquartile range, 2-8).

Primary Outcome: PFS

There were 122 of 127 PFS events in the AM arm and 117 of 127 in the capecitabine arm. The median PFS in the capecitabine arm was 3.88 months (95% CI, 3.65 to 4.37) and 1.87 months (95% CI, 1.81 to 2.14) in the AM arm. Unadjusted and adjusted HRs were 0.44 (95% CI, 0.33 to 0.57), P < .0001 and 0.40 (95% CI, 0.21 to 0.75), P < .0001, respectively. Figure 2 shows Kaplan-Meier curves. Per-protocol analyses demonstrated very similar findings; unadjusted and adjusted HRs were 0.42 (95% CI, 0.32 to 0.55), P < .0001 and 0.38 (95% CI, 0.28 to 0.51), P < .0001, respectively. There was no evidence to suggest deviation from the proportional hazards assumption (P = .084).

0S

There were 90 of 127 deaths in the AM arm and 99 of 127 deaths in the capecitabine arm. The median time to death was 15.2 months (95% CI, 12.1 to 18.5) in the AM arm versus 14.8 months (95% CI, 23.7 to 18.6) in the capecitabine arm, with no survival difference between the arms; unadjusted and adjusted HRs were 1.00 (95% CI, 0.75 to 1.33), P = .98 and 0.93 (95% CI, 0.69 to 1.27), P = .66, respectively. Kaplan-Meier curves are presented in Figure 3. There was no evidence to suggest deviation from the proportional hazards assumption (P = .58).

Subgroup Analyses

Preplanned subgroup analysis for PFS (Fig 4A) suggested better PFS with a maintenance strategy in left-sided tumors (HR 0.38 v 0.56 for right-sided, interaction P = .13), and a similar observation was seen with OS (HR 0.82 for left-sided v 1.37 for right-sided, interaction P = .076; Fig 4B). There was a suggestion that patients with tumoral loss of phosphatase and tensin homolog and *PIK3CA* mutations may show less benefit from maintenance capecitabine than other molecular subgroups (PFS HR 0.74, OS HR 1.47), although this was not statistically significant. For OS, the only other notable subgroup effect was that those with stable disease at random assignment appeared to benefit from maintenance capecitabine, whereas those with partial response did not (OS HR 0.63 and 1.42, respectively, interaction P = .005; Fig 4B). Swimmer plots show the distribution of individual patient PFS duration and timing of CT scans by left- versus right-sided disease (Appendix Fig A1, online only).

Toxicity

Cumulative toxicities were substantially less in the AM arm, with increased toxicities associated with capecitabine maintenance including diarrhea, dry skin, fatigue, nausea, and palmar-plantar erythema (PPE; Fig 5). Ideally, a maintenance therapy should result in no toxicity. Incidence of grade zero as the worst toxicity reported per patient is therefore instructive and is as follows for AM and capecitabine maintenance, respectively: nausea 74% versus




FIG 3. Kaplan-Meier curve for OS in FOCUS4-N. Cox regression HR, adjusted for minimization factors = 0.93 (95% CI, 0.69 to 1.27), P = .66. Minimization factors: location of primary tumor (left, right, and rectum); baseline WHO performance status; baseline disease assessment; No. of metastases; first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody); and biomarker cohort, stratified for FOCUS4 trial timepoints. AM, active monitoring; HR, hazard ratio; OS, overall survival.

67%, diarrhea 72% versus 46%, stomatitis 90% versus 77%, dry skin 83% versus 77%, PPE 87% versus 44%, and anemia 69% versus 54% (Appendix Table A2, online only).

During the trial, 51% of patients who received capecitabine had at least one cycle delayed, 37% had a dose reduction, and 34% missed at least one dose (within a cycle). Fifty percent of capecitabine patients commenced at least four cycles, and 25% commenced at least eight cycles.

QoL

EQ-5D forms were completed in 93% (AM) and 90% (capecitabine) at baseline (prerandomization but postinduction chemotherapy). The Protocol (online only) mandated completion every 8 weeks until progression and 6-monthly thereafter; for analysis purposes, all available forms were forced into an 8-week schedule. On this basis, 63%, 45%, and 33% of randomly assigned patients had data available at 8, 16, and 24 weeks, respectively, with continuous decline thereafter. Modeling was applied to data up to 48 weeks, since data became too sparse beyond this. No notable differences were seen in mobility, self-care, usual activities, anxiety, and depression. There was a suggestion that pain and discomfort might have been experienced less within the capecitabine maintenance arm (P = .11, Fig 6). This may be due to symptoms associated with increased rates of progression in the AM arm.

DISCUSSION

Choices on how to proceed with palliative treatment, in the large majority of patients with incurable mCRC, with stable or responding disease after 16 weeks of first-line therapy need careful consideration with the patient at the core. Discussions must be informed by the impact of receiving systemic anticancer therapy over the preceding period. This should include evaluation of the burden of toxicity and QoL, as well as the response to treatment. Pooled data from key phase II and III trials suggest minimal impact on OS from a maintenance or continuation strategy but do show the ability to delay a return to full combination therapy by implementation of a maintenance therapy. Notably, the FOCUS4-N data support the use of an oral only therapy (capecitabine) to extend PFS and delay a return to combination therapy by an average of two months. There is a clear cost to the patient for this improved PFS seen with maintenance capecitabine including worse toxicity in terms of diarrhea, fatigue, nausea, skin rash, and PPE albeit mostly at grade \leq 2, and these factors should be used to further inform decision making. There was no difference in QoL scores between the two arms. It is notable that the swimmer plots (Appendix Fig A1) suggest that about a third of patients experience an extended PFS beyond 16 weeks with maintenance capecitabine, suggesting significant fluoropyrimidine sensitivity, while a third of patients demonstrate relative insensitivity to fluoropyrimidine monotherapy and may indicate a further need to explore

Adams et al

Subgroup	No. of Patients	HR (95% CI)	P fo Interactio
PTL			
Left-sided	162	0.38 (0.27 to 0.53)	
Right-sided	92	0.56 (0.36 to 0.86)	
Baseline WHO performance stat	JS		
0	157	0.43 (0.31 to 0.61)	.(
1 or 2	97	0.45 (0.29 to 0.69)	
Disease assessment prerandom	zation		
Complete or partial response	155	0.47 (0.33 to 0.66)	
Stable disease	99	0.39 (0.25 to 0.60)	
No. of metastatic sites			
Zero or one	87	0.37 (0.23 to 0.60)	
Two or more	167	0.48 (0.35 to 0.66)	
First-line chemotherapy regimer			
FOLFOX	34	0.28 (0.12 to 0.65)	
FOLFIRI + Cet/Pan	31	0.37 (0.16 to 0.82)	-
FOLFIRI	102	0.44 (0.29 to 0.67)	
CAPOX		0.31 (0.16 to 0.62)	
Others	43	- 0.63 (0.33 to 1.19)	
Platelet count			
< 400 × 10 ⁹ /L	98	0.55 (0.36 to 0.84)	
$\geq 400 \times 10^{9}/L$	8	0.20 (0.02 to 1.97)	
<i>RAS</i> + <i>TP53</i> double mutation			
Yes	59	0.41 (0.23 to 0.74)	
No	141	0.44 (0.30 to 0.63)	
FOCUS4 biomarker cohort	l I		
Nonstratified	27	- 0.50 (0.22 to 1.13)	
BRAF mutation	30	0.35 (0.15 to 0.83)	•
PIK3CA mutation or PTEN loss	40	0.74 (0.38 to 1.44)	
KRAS/NRAS mutation		0.38 (0.24 to 0.60)	
All wild type		0.30 (0.16 to 0.54)	
Overall (unadjusted)	254	0.44 (0.33 to 0.57)	
	0.125 1	1 8	
	Favors Capecitabine	Favors AM	

FIG 4. (A) Forest plot of subgroup analyses for PFS (unadjusted HRs). (B) Forest plot of subgroup analyses for OS (unadjusted HRs). AM, active monitoring; CAPOX, capeciteabine with oxaliplatin; Cet, cetuximab; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; HR, hazard ratio; OS, overall survival; Pan, panitumumab; PFS, progression-free survival; PTEN, phosphatase and tensin homolog; PTL, primary tumor location. (continued on next page)

predictive biomarkers of efficacy for this strategy. Pre- may gain a significant survival benefit from maintenance planned subgroup analysis suggests that patients with stable disease at the end of 16-week induction period

capecitabine, but this is not corroborated in other studies where the same phenomenon was assessed.⁸

	Ne		
Subgroup	No. of Patients	HR (95% Cl)	<i>P</i> fo Interactio
PTL			
Left-sided	162 —	0.82 (0.58 to 1.17)	.07
Right-sided	92	1.37 (0.83 to 2.24)	
Baseline WHO performance stat	us		
0	157 -	1.01 (0.70 to 1.47)	.8
1 or 2	97 —	1.03 (0.65 to 1.63)	
Disease assessment prerandom	ization		
Complete or partial response	155	1.42 (0.97 to 2.10)	.00
Stable disease	99	0.63 (0.40 to 0.99)	
No. of metastatic sites			
Zero or one	87 -	1.20 (0.73 to 1.98)	.4
Two or more	167 —	0.90 (0.64 to 1.29)	
First-line chemotherapy regime	1		
FOLFOX	34 —	1.40 (0.64 to 3.04)	.7
FOLFIRI + Cet/Pan	31	1.12 (0.44 to 2.86)	
FOLFIRI	102	0.84 (0.54 to 1.30)	
CAPOX	44	0.83 (0.40 to 1.72)	
Others	43 —	1.23 (0.60 to 2.53)	
Platelet count			
< 400 × 10 ⁹ /L	98 –	1.23 (0.70 to 2.15)	.5
$\geq 400 \times 10^9/L$	8	0.50 (0.07 to 3.76)	
RAS + TP53 double mutation			
Yes	59 —	1.03 (0.59 to 1.81)	.9
No	141 —	1.02 (0.68 to 1.53)	
FOCUS4 biomarker cohort			
Nonstratified	27	0.99 (0.39 to 2.53)	8.
BRAF mutation	30	1.28 (0.52 to 3.14)	
PIK3CA mutation or PTEN loss	40 -	1.47 (0.71 to 3.06)	
KRAS/NRAS mutation	103 —	0.94 (0.61 to 1.45)	
All wild type	54	0.85 (0.42 to 1.71)	
Overall (unadjusted)	254	1.00 (0.75 to 1.33)	
	0.125	1 8	
	Favors Capecitabine	Favors AM	

FIG 4. (Continued).

Although this trial is underpowered to evaluate OS, it (P = .66) when adjusted for minimization factors. It is demonstrates very similar median values of 14.8 versus informative to compare these data with those of CAIRO3, 15.2 months between the two arms with an HR of 0.93 which compared an AM strategy with capecitabine plus




FIG 5. Cumulative reported toxicity by randomized group: (A) active monitoring (n = 127) and (B) capecitabine (n = 127). G, grade; PPE, palmarplantar erythema.

bevacizumab maintenance with comparable effects on PFS (HR = 0.40, P < .0001; cfFOCUS4-N adjusted HR = 0.40, P < .0001) and nonsignificant OS effect (HR = 0.83, P = .06).⁴ Cross-trial comparisons carry notable caveats and must be undertaken with caution as CAIRO3 included patients with better prognosis than FO-CUS4-N and both their median PFS and cycle number on maintenance therapy were approximately double those of ours. However, it does suggest that the main driver of PFS improvement when using capecitabine plus bevacizumab is the capecitabine. Individual patient data meta-analysis has also shown no OS benefit from current maintenance therapy strategies.⁸

On the basis of a subgroup analysis from the much larger phase III COIN study,¹ which demonstrated a survival detriment in patients with a baseline thrombocytosis receiving a complete treatment break (HR = 1.55; P = .0018), we elected not to recruit patients with baseline thrombocytosis to the FOCUS4 trial program from January 2014 to June 2017. Wishing to validate or refute this finding, we undertook an individual patient data metaanalysis to assess thrombocytosis as a predictive marker of the benefits or otherwise of an intermittent or continuous therapy strategy.⁸ This evaluation did not validate our COIN finding on thrombocytosis, and thus, trial eligibility was adapted to allow these patients to enroll. Within FOCUS4-N overall, 3% (n = 8) of patients had baseline thrombocytosis, and thus, our study is underpowered to explore this predictive phenomenon further. Because of our conservative approach, FOCUS4-N under-represents approximately 25% of patients with mCRC who typically have thrombocytosis at baseline, a known worse prognosis group. However, given our findings in the individual patient data meta-analysis, we do not feel that this undermines our more general conclusions, which are independent of baseline platelet count.

Owing to funding restrictions in the UK National Health Service, bevacizumab is not routinely available for patients with mCRC, and in patients with RAS wild-type tumors, epidermal growth factor receptor monoclonal antibodies are only available in the first-line setting, with restrictions in England preventing treatment interruption of cetuximab/ panitumumab for longer than 6 weeks. Additionally, during the FOCUS4-D trial recruitment period,¹⁰ patients with RAS wild-type and BRAF wild-type tumors were eligible for random assignment and were preferentially recruited into that trial. These factors make for a selective group of patients recruited to FOCUS4-N during that time. From a molecular perspective, 59% of patients randomly assigned in the FOCUS4-N trial had an RAS mutation and 15% a BRAF mutation. Reassuringly, the Forest plots (Figs 4A and 4B) do not show any significant differences in PFS or OS on the basis of these molecular criteria.

In conclusion, despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients entering treatment de-escalation after 16 weeks of induction therapy for mCRC. If maintenance therapy is selected following consideration of the advantages and disadvantages in consultation with a particular patient, capecitabine without bevacizumab may be used to extend PFS, in the interval after doublet or triplet therapy, essentially doubling the period before recommencing fulldose induction therapy. Notably, these data also provide tools to best inform the dialogue between patients and clinicians on the pros and cons of the different approaches and their trade-offs.




FIG 6. Quality of life measured by EQ-5D by randomized group: (A) mobility: X^2 for AUC difference = 0.86(1), P = .35; (B) self-care: X^2 for AUC difference = 1.64(1), P = .20; (C) usual activities: X^2 for AUC difference = 0.06(1), P = .81; (D) pain and discomfort: X^2 for AUC difference = 2.49(1), P = .11; and (E) anxiety and depression: X^2 for AUC difference = 1.03(1), P = .31; AUC, area under the curve.

AFFILIATIONS

¹Centre for Trials Research Cardiff University and Velindre NHS Trust, Cardiff, United Kingdom

²MRC Clinical Trials Unit at UCL, London, United Kingdom

³University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

⁴Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom

⁵Bristol Genetics Laboratory, Bristol, United Kingdom

⁶Western General Hospital, Edinburgh, United Kingdom

⁷Bristol Cancer Institute, Bristol, United Kingdom

⁸Hammersmith Hospital London, London, United Kingdom

⁹University College Hospital London, London, United Kingdom

¹⁰University of Birmingham, Birmingham, United Kingdom

¹¹Aberdeen Royal Infirmary, Aberdeen, United Kingdom

¹²MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom

CORRESPONDING AUTHOR

Louise C. Brown, PhD, University College London, MRC Clinical Trials Unit, 90 High Holborn, London WC1V 6LJ, United Kingdom; e-mail: l.brown@ucl.ac.uk.

EQUAL CONTRIBUTION

 $\mathsf{R.A.A.}$ and $\mathsf{D.F.}$ are joint first authors, $\mathsf{L.C.B.}$ and $\mathsf{T.S.M.}$ are joint last authors.

SUPPORT

Supported by Cancer Research UK and the National Institute for Health Research (NIHR).

CLINICAL TRIAL INFORMATION

ISRCTN#90061546

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JC0.21.01436.

REFERENCES

- 1. Adams RA, Meade AM, Seymour MT, et al: Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12:642-653, 2011
- 2. NCCN: NCCN Guidelines for Patients: Colon Cancer. https://www2.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdf
- 3. Van Cutsem E, Cervantes A, Adam R, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27: 1386-1422, 2016
- 4. Simkens LH, van Tinteren H, May A, et al: Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385:1843-1852, 2015
- 5. Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al: Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16:1355-1369, 2015
- 6. Sherman SK, Lange JJ, Dahdaleh FS, et al: Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer. JAMA Oncol 5: 236-242, 2019
- 7. Sonbol MB, Mountjoy LJ, Firwana B, et al: The role of maintenance strategies in metastatic colorectal cancer: A systematic review and network meta-analysis of randomized clinical trials. JAMA Oncol 6:e194489, 2020
- Adams R, Goey K, Chibaudel B, et al: Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. Clin Cancer Rev 99:102226, 2021
- 9. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009
- 10. Adams R, Brown E, Brown L, et al: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): A phase 2-3 randomised trial. Lancet Gastroenterol Hepatol 3:162-171, 2018

DATA SHARING STATEMENT

Individual deidentified participant data (including data dictionaries) can be shared upon appropriate application to the MRC CTU at any time from full publication. Study protocols and statistical analysis plan have been provided in the Data Supplement with this manuscript. Going forward, it is proposed that data will be shared with an appropriate international collaborative repository to enable future IPD meta-analysis.

AUTHOR CONTRIBUTIONS

Conception and design: Richard A. Adams, David J. Fisher, Janet Graham, Matthew Seymour, Richard Kaplan, Mahesh Parmar, Philip Quirke, Harpreet Wasan, Kai-Keen Shiu, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan Financial support: Janet Graham, Philip Quirke Administrative support: Janet Graham, Richard Kaplan, Harpreet Wasan Provision of study materials or patients: Janet Graham, Matthew Seymour, Susan D. Richman, Philip Quirke, Fiona Collinson, Harpreet Wasan, Leslie Samuel, Richard H. Wilson Collection and assembly of data: Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Susan D. Richman, Rachel Butler, Stephen Falk, Kai-Keen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan Data analysis and interpretation: Richard A. Adams, David J. Fisher, Janet

Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Mahesh Parmar, Philip Quirke, Ewan Brown, Fiona Collinson, Stephen Falk, Harpreet Wasan, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan

Manuscript writing: All authors

Final approval of manuscript: All authors Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The FOCUS4 Trial Investigators full list can be found in Appendix 1.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Richard A. Adams

Honoraria: Merck Serono, Servier, Amgen Consulting or Advisory Role: Merck Serono, Amgen, Servier, Bayer Speakers' Bureau: Merck Serono Research Funding: Merck Sharp & Dohme Travel, Accommodations, Expenses: Servier, Amgen, Merck Serono, AstraZeneca

Janet Graham

Honoraria: Merck Serono, Bristol Myers Squibb, Nucana, Bayer Consulting or Advisory Role: Merck KGaA Travel, Accommodations, Expenses: Nucana

Jenny F. Seligmann

Honoraria: Pierre Fabre, Merck Serono, Servier Consulting or Advisory Role: Pierre Fabre, Roche Molecular Diagnostics Travel, Accommodations, Expenses: Bristol Myers Squibb/Medarex

Matthew Seymour Research Funding: Amgen, AstraZeneca

Richard Kaplan Research Funding: AstraZeneca

Mahesh Parmar Research Funding: AstraZeneca, Astellas Pharma, Janssen, Clovis Oncology

Philip Quirke

Honoraria: Roche Consulting or Advisory Role: Roche, Adlai Nortye, Avacta Life Sciences, Amgen, Bayer

Research Funding: Roche, GeneFirst, ONI

Patents, Royalties, Other Intellectual Property: Roche have filed a patent jointly with my University

Travel, Accommodations, Expenses: Roche, Bayer, Amgen

Rachel Butler

Speakers' Bureau: Bayer, Pfizer, Roche, AstraZeneca, MSD, Illumina, Lilly, Novartis, Amgen, Boehringer Ingelheim

Ewan Brown Research Funding: MSD Oncology

Fiona Collinson

Research Funding: Bristol Myers Squibb

Stephen Falk

Stock and Other Ownership Interests: GlaxoSmithKline Speakers' Bureau: Merck Serono, Servier, Amgen Research Funding: Gilead Sciences Travel, Accommodations, Expenses: Celgene Other Relationship: Servier

Harpreet Wasan

Honoraria: Merck KGaA, Celgene, Sirtex Medical, Servier, Array BioPharma, Roche/Genentech, ERYTECH Pharma, Incyte, Zymeworks Consulting or Advisory Role: Roche Pharma AG, ERYTECH Pharma, Shire, Incyte, Sirtex Medical, Pierre Fabre, Pfizer, Bayer Speakers' Bureau: Sirtex Medical, Celgene, Merck KGaA, Servier, Incyte Research Funding: Sirtex Medical, Merck KGaA, Pfizer, Merck Sharp & Dohme

Kai-Keen Shiu

Honoraria: Merck Serono, MSD Oncology, Innovent Biologics, Servier, Daiichi Sankyo Europe GmbH Consulting or Advisory Role: MSD Oncology, Roche, Mirati Therapeutics Research Funding: MSD Oncology, Roche

Gary Middleton

Consulting or Advisory Role: BMS, D2G, MSD Speakers' Bureau: Roche, BMS, Servier, PierreFabre, AZ Travel, Accommodations, Expenses: BMS

Leslie Samuel Honoraria: Servier Consulting or Advisory Role: Merck Research Funding: Merck, Array BioPharma, Tesaro, Servier, Hutchison MediPharma

Richard H. Wilson

Honoraria: Servier, Amgen, Bristol Myers Squibb Consulting or Advisory Role: Amgen, CV6 Therapeutics, Pierre Fabre, Amphista Therapeutics, Nucana Travel, Accommodations, Expenses: Amgen, Pierre Fabre

Louise C. Brown Research Funding: AstraZeneca

Timothy S. Maughan Consulting or Advisory Role: AstraZeneca, Vertex, Pierre Fabre Research Funding: AstraZeneca, PsiOxus Therapeutics, Merck KgAA, Almac Diagnostics

No other potential conflicts of interest were reported.

APPENDIX 1. FULL AUTHORSHIP LIST FOR THE FOCUS4 TRIAL INVESTIGATORS

Writing Committee for FOCUS4-N Trial

Adams R., Fisher D.J., Graham J., Seligmann J.F., Seymour M., Kaplan R., Yates E., Parmar M., Richman S.D., Quirke P., Butler R., Brown E., Collinson F., Falk S., Wasan H., Shiu K., Middleton G., Samuel L., Wilson R.H., Brown L.C., Maughan T.S.

Trial Management Group

Maughan T.S. (Chair), Wilson R., Adams R., Seymour M., Seligmann J.F., Graham J., Wasan H., Pope M., Pope J., Samuel L., Shiu K., Church D., Middleton G., Steward W., Twelves C., Wellman S., Hodgkinson E., Stoner N., Beety J., Duggleby K., Dutton G., MRC CTU team (below), laboratory staff (see below).

MRC CTU trial coordinating centre

Brown L.C., Kaplan R., Parmar M., Fisher D.J., Campos M., Yates E., Santana S., Fiddament A., Harper L., Bara A., Pugh C., Bathia R., Letchemanan K., Przybył B., Bhogal S., Gopalakrishnan G., Purvis C., Diaz-Montana C., Mohamed F., Townsend S., Cragg W., Masters L., Van Looy N., Rauchenberger M.

Laboratories

Quirke P., Richman S.D., Hemmings G., Davis J., Gallop N., Wilkinson L., Butler R., Roberts H., Jasani B., White R., Dodds R., James M., Morgan M.

Independent Data Monitoring Committee

Cameron D. (Chair), Souhami R., Peeters M., Billingham C., Griffiths G., Brown J.

Trial Steering Committee

Johnson P. (Chair), Rudd R., Whelan J., Russell A.

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076)

Hospital	First Name	Surname (principal investigator [PI])
Western General Hospital	Ewan	Brown (PI)
	Morven	Atkinson
	Caroline	Bruce
	Patricia	Campbell
	Sally	Clive
	Kathryn	Connolly
	Lorraine	Cook
	Helen	Creedon
	Judith	Crawford
	Alisa	Davinson
	Lesley	Dawson
	Grace	Ding (Tze-en Ding)
	Martin	Doak
	Tamasin	Doig
(co	ntinued in next col	umn)

Hospital	First Name	Surname (princip investigator [PI]
loopital	Clare	Dunbar
	Ben	Elliott
	Lynne	Faragher
	Paul	Fineron
	Nikki	Gilluley
	Ewa	Kondarewicz
	Jenifer	Lauchlan
	Jim	Macpherson
	Catriona	Mclean
	Hazel	Milligan
	Suzanne	Muir
	Alisa	Oswald
	Ashley	Pheely
	Hamish	Phillips
	Kelly	Rust
	Shaafia	Siddiqui
	Barbara	Stanley
	Moira	Stewart
	Vivienne	Wilson
St James's University Hospital (Leeds)	Fiona	Collinson (PI)
	Matt	Seymour (PI)
	Humaira	Abbas
	Ifeoluwa	Ajibayo
	Alan	Anthoney
	Hana	Ali
	Orrie	Appell
	Andrew	Barker
	Vincent	Barlow
	Shanaz	Begum
	Maxine	Berry
-	Judith	Chapman
	Sam	Charlton
	Pam	Clark
	Emily Rose	Crawford
-	Anne	Crossley
	Gemma	Dart
	Jessica	Docherty
	Irina	Ershova
	Alexandra	Firth
	Jeanifer	Gachev
	Leanne	Galloway-Browne

Participating Hospitals in Descending Order of the Number of Patients

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Jillian	Hanson		Julie	Graham
	Amelie	Harle		Jill	Halpin
	Farzana	Haque		Robert	Henley
	Janine	Heeley		Lynda	Holman
	Jane	Hook		Alys	Irving
	Jane	Hughes		Amanda	Jackson
	Alison	Judge		Emma	John
	Emma	Livesey		Rhianydd	Jones
	Emma	Lundy		Colette	Kemp
	Michael	O'Brian		Satish	Kumar
	Mike	Osborne		Claire	Lang
	Lauren	Paul		Cindy	Langford
	Mary	Perrin		Debbie	O'Connor
	Annet	Pillai		Diana	Osman
	Charlotte	Richardson		Catherine	Matthews
	Suzanne	Rogerson		Ross	McLeish
	Olorunda	Rotimi		James	Morgan
	Emily	Rudolph		Phillip	Morgan
	Jenny	Seligmann		Renata	Poole
	Hannah	Shanks		Karen	Pow
	Daniel	Swinson		Joanne	Preece
	Danny	Ulahannan		Cathy	Richards
	Mariah	Vorajee		Jayne	Richards
	Sarah	Wetherop		Rosie	Roberts
	Hannah	Wigginton		Sharon	Rogers
	Christopher	Williams		Jodie	Sherburn
	Jawairiya	Zubair		Lisa	Stafford
elindre Hospital	Rob	Jones (PI)		Catherine	Sullivan
	Richard	Adams (PI)		Hana	Thomas
	Seema	Arif		Anshu	Wadhawan
	Rebecca	Bethell		Catherine	Watkins
	Kathy	Bishop		Hilary	Williams
	Alison	Brewster		Rachel	Williams
	Michael	Brown		Kay	Wilson
	Julie	Broughton		Rebecca	Wilson
	Lucy	Chestney		Cheryl	Worsey
	Nikki	Coates		Charlotte	Young
	Sonali	Dasgupta	Christie Hospital	Michael	Braun (PI)
	Karen	Davies		Jo	Allen
	Clare	Donnithorne	_	Hannah	Arhinful
	Beverley	Eley		Janet	Beech
	Maria	Evans		Martin	Birch

Participating Hospitals in Descending Order of the Number of Patients	
Registered With All Staff Listed (N = $2,076$) (continued)	

	Anna	R evente re			
		Bowron		Alice	Dewdney
	Suzanne	Carter		Julia	Disney
	Jackie	Connell		Lynne	Dixon
	Camille	Cooney		Paul	Dodd
	Rebecca	Cox		Sarah	Gill
	Olive	Craven		Elizabeth	Hodgkinson
	Mark	Cutting		Helen	Joyce
	Hannah	Downs		Mandip	Khaira
	Karen	Forshaw		Panagiota	Kitsanta
	Chloe	Gawlik		Jasima	Latif
	Jurjees	Hasan		Laura	Lee
	Sarah	Hughes		Cathryn	Leng
	Paul	Husbands		Tony	Matthew
	Mary	Jepson		Eileen	Marsh
	Konstantinos-	Kamposioras		Aimee	Pendlebury-Worrad
	Vellios			Megan	Perry
	Rhea	Langeveld		Simon	Pledge
	Catherine	McBain		Muneeb	Qureshi
	Danielle	McCool		Alison	Redfearn
	Saifee	Mullamitha		Helen	Shulver
	Monica	Narasimham		Helen	Slater
	Alkesh	Patel		Laura	Smith
	Jane	Rogan		Svetlana	Solovieva
	Mark	Saunders		Catherine	Spalton
	Sue	Seifi		Elisavet	Theodoulou
	Lilly	Simpson		Lucy	Walkington
_	Greg	Wilson		Christopher	Walls
	Marie	Woolley		Mary	Ward
Veston Park Hospital	Joanne	Hornbuckle (PI)		Katherine	Williams
	Jess	Aldred		Vanessa	Wilshaw
	Cyper	Allan		Robin	Young
	Richard	Allen	Bristol Haematology	Stephen	Falk (PI)
	Lynne	Ashmore	and Oncology Centre		
	Darrell	Barrott		Elizabeth	Allison
	Alex	Bradshaw		Paul	Armenise
	Richard	Brown		Lindsay	Ball
	Sarah	Brown		Helen	Brooks
	Kevin	Chan		Paula	Byrne
	Rachael	Clarke		Carlota	Clemente
	Su	Clark		Marc	Coe
	Susan	Clenton		Kiril	Delchev
	Richard	Crossley		Kay	Drury

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Emily	Foulstone		Jane	Crozier
	Elysia	Gower		Samantha	Curtis
	John	Helbrow		Michael	Daly
	Jon	Heywood		Claire	Dyke
	Robert	Hollister		Rachael	Exley
	Kirsten	Hopkins		Ioana	Fodor
	Hollie	Jones		Yuko	Francis
	Lauren	Joyce		Sharath	Gangadhara
	Helen	Kingston		Amy	Gaunt
	Jayne	Leonard		Jenny	Gilbert
	Amelia	Lowe		Beatrice	Hamilton
	Catherine	McDonald		Leonie	Harrison
	Helen	Monnington		Carly	Laxon-Takooree
	Katarina	Milutinovic		Jill	MacDonald-Burn
	Jessica	Nuttall		Katarzyna	Machura
	Yasmin	Odding		Margaret	Macmillan
	Ronak	Patel		Carey	Milsom
	lan	Penwarden		Kate	Moloney
	Peter	Robertson		Sarah	Murdoch
	Tim	Robinson		Joseph	Needham
	Sharon	Short		Abigail	Pocock
	Thomas	Strawson-Smith		Vicki	Portingale
	Kirsty	Stevenson		Bryony	Robertson
	Hannah	Taylor		Annie	Taylor
	Sandra	Williams (nee Price)		Eve	Tomlinson
	Eve	Watson		Tom	Tylee
	Axel	Walther		Rebecca	Wassall
	Angela	Webb		Samantha	Williams
	Tom	Wilson		Jess	White
	Roland	Wynn-Williams	Castle Hill Hospital	Rajarshi	Roy (PI)
Royal United Hospital	Emma	De Winton (PI)		Abigail	Alford
	Louise	Medley (PI)		Katie	Broadbent
	Tania	Allen		Amandeep	Dhadda
	Rowan	Appleby		Ceri	Fuller
	Claire	Barron		Laura	Hart
	Leigh	Biddlestone		Lyn	Harrison
	Hannah	Blades		Joanne	Hinchcliffe
	Ruth	Brydon-Hill		Linda	Hoggarth
	Shaolin	Chidavaenzi		Rhian	Horne
	Ashley	Cox		Dawn	Jones
	Christine	Cox	·	Louise	Karsera
	Claire	Craige		Magdalena	Kolodzieg
loor	ntinued in next co	-		ntinued on following	

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Daniel	Lee		David	Barber
	Lisa	Nix		Stephanie	Cornthwaite
	Paula	O'Reilly		William	Croxford
	Kristian	Plowman		Parth	Desai
	Karen	Shepherd		Kay	Ellel
	Karen	Stubbs		Cassandra	Gleeson
	Gabrielle	Taft		Louise	Hough
	Reenee	Tiam		Krishna	Panchal
	Adam	Wolstencroft		Shakeelah	Patel
/ictoria Hospital (Blackpool)	Sin	Lau (PI)		Mark	Pitt
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Charlotte	Armer		Sarah	Preston
	Denise	Bennett		Andrew	Martyniak
	Caroline	Boardman		Aasif	Motala
	Oliver	Brennan		Deborah	Williamson
	Laura	Collins		Claire	Searle
	Falalu	Danwata		Shabbir	Susnerwala
	Alexander Paul	Davies		Dorothy	Walmsley
	Emma	Davies		Saif	Yousif
	Leanne	Davies	Musgrove Park Hospital		Ratnayake (PI)
	Stacey	Donaldson		Clare	Barlow (PI)
	Hannah			Jan	Ashcroft
	Amanda	Ferguson		Hilary	Barlow
		Finch		Nita	Beacham
	Julie	Frudd		Erica	Beaumont
	Karen	Gratrix		Hannah	Berry
	James	Haston		Becky	Brown
	Sue	Hesketh		Clair	Brunner
	Sue	Lancaster		Richard	Burgess
	Chris	Pemberton		Alison	Chedham
	Karen	Pollard		Hayley	Cornall
	Andrew Jonathan	Potter		Nicola	Cutmore
	Toni	Purcer		Flora	Darch
	Ella	Riedel		Natasha	Eveleigh
	Nicola	Slawson		John	Geraghty
	Shabbir	Susnerwala		Fiona	Goodchild
	Lauren	Thornborough		Emma	Gray
	Conor	Wilkinson		Clair	Hinton
	Mark	Wrigley		Lucy	Howell-Drewett
Royal Preston Hospital	Sin	Lau (PI)		Joan	Kemp
ioyai Fresion Hospilai	Amanda	Alty		Catherine	Lane
		Antrobus		Fen	Lewen
	Philippa			Dee	Lewis
	Katherine tinued in next col	Ashton	(conti	nued on following	g page)

© 2021 by American Society of Clinical Oncology

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Angela	Locke		Sarah	Stimpson
	Sue	Mahoney		Regina	Storch
	Samantha	Northover		Caroline	Ward
	Joanne	Rogers		Adrian	Zebrowski
	Guillermo	Reina-Ruiz	Huddersfield Royal	Jo	Dent (PI)
	Јоу	Rowe	Infirmary		
	Alison	Snell		Zenab	Ahmed
	Luke	Stephens		Mohammad Irfan	Alam
	Joanne	Taylor		Nick	Brown
	Rebecca	Twemlow		Sam	Dale
	Rebecca	Wallbutton		Nicky	Daker
	Jasmine	Youens		Denise	Hancock
	Robert	Zorica		James	Harris
	Maria	Zietz			
Hammersmith Hospital	Harpreet	Wasan (PI)	·	Lisa	Horner
	Ilyas	Ali		Ibrar	Hussain
	Nawa	Amin		Jeremy	Hyde
	Gareth	Barker		Paula	Gomes
	Michelle	Chen	-	Rebecca	Jenkins
	Sarah	Chilcott-Burns	-	Christopher	Knight
	James	Clark	-	Adam	Mawer
	Susan	Cleator	-	Mandy	Madigan
	Christopher	Coyle	-	Belinda	McLean
	Andrea	Davis-Cook	-	Sabiha	Ravat
	Keyury	Desai	-	Hannah	Riley
	Matthew	Flook		Jodie	Rowan
	Victoria	Harding		Simone Deborah	,
	Gillian	Hornzee		Lisa	Shaw
	Victoria	Latham		Selina	Shaw
	Luzviminda	Llemit Ramos		Kathryn	Smith
	Charles	Lowdell		Christine	Turner
	Maria	Martinez		Georgina	Turner
	Daniel	Meredith		Hayley	Webster
	Laura	Morland		Tracy	Wood
	Annette	Musallam	Northampton General Hospital	Roshan	Agarwal (PI)
	Chynna	Pascual		Sabri	Ahmed
	Emily	Pickford		Caroline	Duncombe
	David	Pinato		Tasnim	Ebrahimjee
	Keira	Pudge		Rachel	Gabitass
	Ramya	Ramaswami		Ethelwolda	Goyena
	Azeem	Saleem		Andrea	Hillyer
	Amalia	Saucan		Jane	Hosea
	tinued in next co			inued on following	

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Mohammad	Hussain		Andrew M	Jackson
	Kashif	Jarral		Annette	Jones
	Andrea	Jones		Konstantinos-	Kamposioras
	Andrea	Kempa		Vellios	
	Adnan	Masood		Patricia	Kane
	Craig	Macmillan		Tracey	Lowry
	James	Maloy		Stephanie	Lupton
	Katherine	McGrath		Joanna	Lyle
	Jan	Miles		Kate	Norton
	Onyinye	Ndefo		Ganesh	Radhakrishna
	Paula	O'Connell		Vishal	Ramdhani
	Malgorzata	Polnik		Muhammad Bilal	Razzaq
	Ehsan	Rahman		Ayesha	Sheikh
	Shahriar	Reza		Hira	Yousif
	Mohammed Sharon	Puon	Beatson West of Scotland Cancer	Janet	Graham (PI)
	Simon	Ryan	Centre		
		Stapley		Tareq	Abdullah
	Elizabeth	Tee		Ghada	Al-Salih
1	Lenka	Zvirinska		Martin	Ball
Pinderfields Hospital	lva	Damyanova (PI)		Karen	Bell
	Ashraf	Alkhaldi (PI)		Anette	Charlick
	Gireesh	Kumaran (PI)		Maureen	Connolly
	Usman	Ahmad		Jill	Dempster
	Aneeka Shubnum	Altaf		Alan	Foulis
	Julie	Ball		Paula	Henry-Stephenson
	Louise	Benton		Jill	Graham
	Kevin	Birbeck		Lesley	Hickey
	Lynsey	Bourner		Sandra	Jenkins
	Richard	Bowers		Sai Juan	Jia
	Hollie	Brooke		Jennifer	Keith
	Ellis	Burton		Donna	Kelly
	Julie	Burton		Audrey	Leonard
	Deborah	Cooper		Gail	Lynch
	Elizabeth	Clayton		Alex	McDonald
	Jane	Eastwood		Jordan	McGill
	Aimee	Fletcher		Anne	McKillop
	Rebecca	Foster		Austin	McInnes
	Darren	Gomersall		Fiona	McQueen
	Hassan	Hameed		Nazia	Mohammed
				Paul	Mooney
	Aimee	Hayton-Bott		Maria	Nygren
	Charlotte	Hirst		Shilpa	Thapar
	Claire	Hutsby		ntinued on following	

© 2021 by American Society of Clinical Oncology

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Kirsty	Ross		Abimbola	Barango
	Patricia	Roxburgh		Balazs	Binnyei
	Pavlina	Spiliopoulou		Gillian	Brand
	Eileen	Soulis		Kay	Campbell
	Kirsteen	Stuart		Angie	Cheyne
	Rasheed	Syed		Michael	Christie
	Ashita	Waterston		Kathryn	Connolly
	Cheryl	Wilson		Pat	Cooper
Ysbyty Gwynedd	Catherine	Bale (PI)		Amber	Johnson
Ke Na Cla	Kelly	Andrews		Susan	Martin
	Naomi	Boyle		Celia	Meneses
	Claire	Fuller		Graeme	Murray
	John	Grant		Nicola	Price
	Emma	Hall		Sue	Rodwell
	Anna	Mullard		Mhairi	Scott
	Wendy	Saxton		Margaret	Smith
	Nick	Stuart		Bartosz	Was
	Alice	Thomas		Mehmood	Zaidi
	Linzi	Williams		Ishtiag	Zubairi
	Rachel	Williams	Cheltenham General	Kim	Benstead (PI)
Withybush General Hospital	Sarah	Gwynne (PI)	Hospital	Jaqueline	Aberdeen
	Maung	Moe (PI)		Rehana	Bakawala
	Fawwaz	Arikat		Sarah	Beazer
	Denisa	Asandei		Colin	Binks
	Sandra	Evans		Lucy	Blake
	Eirianydd	Garrard		Bethan	Cartwright
	Sophie	Glynn-Williams		Samuel	Croly
	Colette	Griffiths		Lin	Crossley
	Rachel	Hughes		Rachel	Durrant
	Catherine	MacPhee		David	Farrugia
	John	Murphy		Janet	Forkes
	Kirsty	Pope		Emma	Gilbert
	Rocio	Riba		Fabrizio	Mauri
	Sally-Ann	Rolls		Elaine	Pratten
	Abigail	Taylor		Elisabeth	Read
	Carol	Thomas		Nick	Reed
	Helen	Thomas		Rachel	Sayers
	Vallipuram	Vigneswaran		Neil	Shepherd
Aberdeen Royal	Leslie	Samuel (PI)		Stephen	Shepherd
Infirmary	Leslie	Samuer (FI)		Jennifer	
	Fay	Annison			Smith
				Sarah	Stanley

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Catherine	Stuart-Grumbar		Shirley	Todd
	Bilal	Торіа		Jane	Thompson
	Kate	Trigg-Hogarth		Fiona	Walters (nee Hall)
Clatterbridge Centre for Oncology	Nasim	Ali (PI)		Claire	Webb
	Wesley	Artist		Julia	Weston
	Shaker	Abdallah	Southampton General Hospital	Tim	lveson (PI)
	Alexandra	Bailey		Liane	Armstrong
	Danielle	Campbell		Andrew	Bateman
	Maggie	Cantrell		Adrian	Bateman
	Joanne	Cliff (nee Mooney)		Emma	Brown
	Thomas	Davies		Holly	Burton
	Helen	Flint		Тгасеу	Callen
	Amy	Ford		Bethany	Caruana
	Barbara	King		Caroline	Chau
	Ayman	Madi		Тгасеу	Day
	Samah	Massalha		Efe	Evbuomwan
	Laura	McAllister		Meg	Gale
	Amir	Montazeri		Julie	Gwilt
	Joanne	Mullen		Sara	Hosseini-Moein
	Julie	O'Hagan		Alice	Johnson
	Anna	Olsson-Brown		Leah	Long
	Katharine	Pelton		Steve	McKenzie
	Kelly	Richardson		Charlotte	Rees
	Sandra	Robinson		Rasha	Said
	Joseph	Sacco	University College	John	Bridgewater (PI)
	Sarah	Stuart	Hospital		
	Hollie	Wilson		Adrienne	Abioye
	Pembe	Yesildag		Mahfuja	Ahmed
	Mariah	Zavery		Shamima	Akther
Royal Devon and Exeter	Melanie	Osborne (PI)		Maise	Al Bakir
Hospital				Adelaide	Austin
	Kizzy	Baines		Holly	Baker
	Tamika	Chapter		Jaytee	Barnett
	Elizabeth	Davey		Nina	Bason
	Susan	Downer		Isabelle	Brown
	Dawn	Edwards		Alexa	Childs
	Theresa	Lawless		Louise	Coyle
	James	Leavy		Patricia	Danaswamy
	Mark	Napier		Kanishka	Dissansayke
	Emma	Robjohns		Rosina	Donovan
	Patrick	Sarsfield		Lola	Enemuwe
	Ingrid	Seath		Victor	Eneh

© 2021 by American Society of Clinical Oncology

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Gabrielle	Gould		Katie	Douglas
	Todd	Gumbleton		Grainne	Dunn
	Selina	Gurung		Mohammed	El-Abdullah
	Gemma	Hector		Lynn	Glass
	Sonya	Hessey		Kirsteen	Hamill
	Daniel	Hochhauser		Susan	Hastings
	Sabrina	Holohan		Rebecca	Heron
	Michelle	Hung		Chloe	MacDonald
	Georgios	Imseeh		Steven	Marshall
	Adoracion	Jayme		Laura	Miller
	Sarah	Kerr		Geradline	O'Dowd
	Khurum	Khan		Aqilah	Othman
	Jennifer	Laude		Diana	Park
	Xiao	Lu		Angela	Scullion
	Gina	Margai		Denise	Vigni
	Katie	Matthews		Kai	Yahya
	Eman	Mohamad	Charing Cross Hospital	Harpreet	Wasan (PI)
	Fatima	Mohamed		Thalia	Afxentiou
	Sam	Morris		Riz	Ahmed
	Anna	Nikopoulou		Melloney	Allnutt
	Mayur	Patel		Gareth	Barker
	Maria	Power		Abigail	Caldow
	Prakash	Rao		Jolene	Carioni
	Manuel	Rodriguez-Justo		Sarah	Chilcott-Burns
	Derya	Sahin		Andrea	Davis-Cook
	Kai Keen	Shiu		Yomi	Fatola
	Luke Owen	Steventon		Chee	Goh
	Mark	Sunga		Dorothy	Gujral
	Hinesh	Tailor		Gillian	Hornzee
	Anisa	Tariq		Eleni	Josephides
	Varji	Thayalan		Charlotte	Kelly
	Jennifer	Thomas		Daleep	Kumar
	Christopher	Wanstall		Priya	Limbu
	Kristian	Warnes		Luzviminda	Llemit Ramos
	Christopher	Whitton		Charles	Lowdell
	Georgina	Wood		Sophia	Magwaro
Monklands Hospital	Lisa	Rogers (PI)		Rochelle	McIntyre
	Anne	McKillop (PI)		Philippa	Nutkins
	Ashita	Waterston (PI)		Shola	Ogegbo
	Paula	Botham		Anna	Osei-Kofi
	June	Carr		Susan	Ramsey
	Louise	Devlin	-	Pippa	Riddle
(cc	ontinued in next co	lumn)	(conti	nued on following	g page)

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

> Surname (principal investigator [PI])

Registered With All Stat Hospital	First Name	Surname (principal investigator [PI])	Registered With All St	First Name	Surname (pri investigator
	Amalia	Saucan		Anthony	Wilson
	Helen	Saxby		Rebecca	Wiltshire
	Chantelle	Simpson		Martha	Woodward
	Aspa	Spyrou		Kirsten	Wynn
	Kirsty	Tunna	Leicester Royal	Anne	Thomas (PI)
	Iman	Yahya	Infirmary		
	Adrian	Zebrowski	·	Will	Steward (PI)
Churchill Hospital, Oxford	Tim	Maughan (PI)		Elizabeth Tracey	Andrzejewski Alexander
	David	Badcock		Sarah	Attridge
	Magdalena	Benysek		Julie	Barlow
	Rosita	Broderick		Theresa	Beaver
	Anne	Butterfield		Amy	Branson
	Evelyn	Chan		Meera	Chauhan
	Philip	Charlton		Aurora	Del Pozo
	David	Church		Hadia	Haque
	Richard	Cousins		Hannah	Holdsworth
	Louise	Cowen		Rahima	Ibrahim
	Joanne	Davies		Chinenye	Iwuji
	Steven	Davis		Mohammed	Karolia
	Alfonso	Gonzalez Blas		Lydianne	Lock
	Will	Goodman		Mohammed	Mahgoub
	Nikki	Hayward		Adrian	Nicholson
	Clare	Jacobs		Ahmed	Osman
	Patrycja	Jastrzebska		Katherine	Perkins
	Evanthia	Komninidou		Sarah	Porter
	Jonathan	Lau		Thiaghrajon	Sridhar
	Carolina	Lepiato		Judith	Underwood
	Clare	Marken		Balaji	Varadhan
	Kerrie	Marston		Julia	Walker
	Mark	Middleton		Kevin	West
	Ann	Murphy		Joanna	Wood
	Rebecca	Muirhead	Raigmore Hospital	Walter	Mmeka (PI)
	Adrian	Nicholson		Anglise	Addison
	Robin	Peach-Toon		Seonaid	Arnott
	Navin	Pol		Karen	Callum
	Sally	Rich		Denise	Campbell
	Nicola	Stoner		Fiona	Campbell
	James	Wakelin		Kay	Kelly
	Lai Mun	Wang		Alison	Macdonald
	Andrew	Weaver		Angela	Macgregor
	Sandie	Wellman		Carol	Macgregor

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Zoe	Maciver		Gemma	Cook
	Laura	Maclennan		Amelia	Daniel
	Jude	Madeleine		Venkatesh	Gajapathy
	Melanie	McIlroy		Evelyn	Holmes
	Mary	McKenzie		Тауо	Jaiyesimi
	Neil	McPhail		Joanne	Kellaway
	Alison	Nicholls		Teresa	Light
	Marion	Paterson		Lucinda	Melcher
	Leslie	Samuel		Cait	Rees
	Georgina	Simpson		Vasi	Sundaresan
	Glenda	Sinclair	Royal Surrey County	Tony	Dhillon (PI)
	Feng Yi	Soh	Hospital		
	Grant	Stenhouse		Mazhar	Ajaz
	Joan	Stewart		Nawa	Amin
	Una	Taylor		Humyraa	Aziz
	Zoe	Urquhart		Izhar	Bagwan
(Kirkcaldy)	Sally	Clive (PI)		Catherine	Blake
				Fiona	Butler
	Brian	Adamson		Penny	Champion
	Julie	Aitken		Karen	Chan
	John	Brush		Sebastian	Cummins
	Rebecca	Cain		Tineke	Edmunds
	Lesley	Cargill		Sharadah	Essapen
	Shona	Cheyne		Andrew	Furness
	Clare	Cliff		Laura	Gordon
	Hazel	Cree		Di	Grainger
	Karen	Gray		Helen	Graves
	Sophie	Iwanikiw		Imogen	Heenan
	Fiona	Johnston		Kirsty	Horwood
	Alastair	Matthews		Daniel	Jennings
	Wendy	McCorry		Natasha	Kamboh
	Catriona	Mclean		Aga	Kehinde
	Fiona	Murdoch		Karla	Lee
	Ibrahim	Nawroz		Sibylle	Lintott
	Julie	Penman		Gaybrielle	Livingstone
	Anna	Scott		Cheryl	Marriott
	Maria	Simpson		Catherine	Medcalf
	Deepak	Subedi		Aruna	Medisetti
	Jennifer	Tait		Mahomed	Moosa
	Michelle	Tingley		Gayathri	Nagarajan
	Linzi	Wilson		Sarah	Oakes
Princess Alexandra	John	Bridgewater (PI)		Sue	Sargent
Hospital (Harlow)			(con	tinued on following	

Participating Hospitals in Descending Order of the Number of Patients	
Registered With All Staff Listed (N = $2,076$) (continued)	

Hospital	First Name	Surname (principal investigator [PI])
	Alexandra	Stewart
	Hasina	Thandar
	Claire	Thompson
	Katharine	Webb
	Rosalyne	Westley
	Julia	Whittle
	Julie	Wilkinson
	Rebecca	Wills
St Helens Hospital	Zahed	Khan (PI)
	Rachel	Cassidy
	Jenny	Cotton
	Lisa	Dobson
	Nicola	Hornby
	Sheila	Kelly
	Amanda	McCairn
	Jeanette	Ribton
	Michelle	Robinson
	Carol	Ross
	Victoria	Thomas
hesterfield Royal Hospital	Vanessa	Wilshaw (PI)
	Ibrahim	Al-Modaris
	Rebecca	Clark
	Aurora	Del Pozo
	Alice	Dewdney
	Nicky	Ford
	Rachel	Gascoyne
	Neeta	Gogna
	Charlotte	Hoult
	Emma	Hudson
	Kelly	Pritchard
	Martin	Shepherd
	Lesley	Stevenson
	Danesh	Taraporewalla
	Julie	Toms
	Katie	Wallace
	Julie	Whitehead
	Lucinda	Wilson
pswich Hospital	Gopalakrishnan	Srinivasan (PI)
	Zoltan	Szucs (PI)
	Deborah	Abrams
	Debbie	Austin

Carlos Matthew Natalie Rita Paul Kirubah Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	Gonzalez Howlett Lloyd Ng Ridley Selvaraj Sherwin Sivarajah Upson Williams Wong Nolan (PI) Beattie Conti
Natalie Rita Paul Kirubah Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	Lloyd Ng Ridley Selvaraj Sherwin Sivarajah Upson Williams Wong Nolan (PI) Beattie
Rita Paul Kirubah Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	NgRidleySelvarajSherwinSivarajahUpsonWilliamsWongNolan (PI)Beattie
Paul Kirubah Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	Ridley Selvaraj Sherwin Sivarajah Upson Williams Wong Nolan (PI) Beattie
Kirubah Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	Selvaraj Sherwin Sivarajah Upson Williams Wong Nolan (PI) Beattie
Liz Bamini Susan Angharad Jason Luke Louise Julie Duncan	Sherwin Sivarajah Upson Williams Wong Nolan (PI) Beattie
Bamini Susan Angharad Jason Luke Louise Julie Duncan	Sivarajah Upson Williams Wong Nolan (PI) Beattie
Susan Angharad Jason Luke Louise Julie Duncan	Upson Williams Wong Nolan (PI) Beattie
Angharad Jason Luke Louise Julie Duncan	Williams Wong Nolan (PI) Beattie
Jason Luke Louise Julie Duncan	Wong Nolan (PI) Beattie
Luke Louise Julie Duncan	Nolan (PI) Beattie
Louise Julie Duncan	Beattie
Julie Duncan	
Duncan	Conti
	Cooke
Victoria	Corner
Adrienn	Fazekasne Fulep
Angela	Frith
Julie	Gwilt
Samantha	Hammond
Liz	Happle
Lesley	Hollister
Roger	Hudson
Abigail	Hughes
Lauriane	Kerwood
Matthew	Pitt
Balvinder	Shoker
Rao	Vuyyuru
Catherine	Jephcott (PI)
Terri-Anne	Baker
Helen	Bowyer
Kerrie	Cavanagh
Rebecca	Chilvers
Marilyna	Chong
Laura	Costello
Abigail	Hollingdale
Steph	Lawrence
Heather	Maccoll
Carla	Martino
Claire	Palombo
Stuart	Richmond
	Victoria Adrienn Angela Julie Samantha Liz Lesley Roger Abigail Lauriane Matthew Balvinder Balvinder Rao Catherine Catherine Helen Kerrie Rebecca Marilyna Laura Abigail Steph Heather Carla Calire

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Но
	Richard	Skells	
	Laura	Simon	
	Claire	Snowden	
	Lisa	Wilde	
	Louise	Wilmer	
Calderdale Royal Hospital	Jo	Dent (PI)	
	Mohammad Irfan	Alam	
	Nick	Brown	
	Nicky	Daker	
	Sam	Dale	
	Denise	Hancock	
	James	Harris	
	Lisa	Horner	M
	Jeremy	Hyde	
	Rebecca	Jenkins	
	Christopher	Knight	
	Mandy	Madigan	
	Adam	Mawer	
	Belinda	McLean	·
	Sabiha	Ravat	·
	Hannah	Riley	·
	Jodie	Rowan	
	Simone Deborah	Ryan	
	Lisa	Shaw	·
	Selina	Shaw	·
	Kathryn	Smith	
	Christine	Turner	
	Georgina	Turner	
	Hayley	Webster	
	Tracy	Wood	
Derriford Hospital	David	Sherriff (PI)	
	Rebecca	Aaron	
	Bridget	Aire	
	Baffour	Amo-Takyi	
	Erin	Brennan	
	Lucy	Cadmore	
	Leonie	Eastlake	Тс
	Laura	Evenden	
	Kay	Facey	
	Olivia	Fraser	
	Julie	Froud	

Hospital	First Name	Surname (principal investigator [PI])
	Bojidar	Goranov
	Irene	Harvey
	Maggie	Kalita
	Sarah	Kingdon
	Mike	Marner
	Laura	Marks
	Susan	McFarlane
	Chelsea	Morton
	Anna	Mucha
	Sarah	Prance
	Olivia	Reed-Poysden
	Peter	Sankey
	Helen	Smith
Macclesfield District General Hospital	Victoria	Lavin (PI)
	Ganesh	Radhakrishna (PI)
	Catherine	McBain (PI)
	Victoria	Adinkra
	Dane	Bradwell
	Lisa	Brookes
	Helen	Burns
	Nicola	Dawson
	Catherine	Fenson
	Lisa	Hardstaff
	Abbi	Henderson
	Christy	Henderson
	Pippa	Hill
	Debra	Jowle
	Mark	Lawrence
	Joanna	Longden
	Nicola	Lunt
	Marilyn	McCurrie
	Karen	Rotchell
	Barbara	Townley
	Helen	Wassall
	Julie	Whitehead
	Lesley	Wilkinson
	lain	Woodhouse
Torbay District General Hospital	Nangi	Lo (PI)
	Michele	Allison
	Kenneth	Almedilla

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (princip investigator [PI]
	Lauren	Blunt		Svitlana	lyevkova
	Jo	Blurton		Rashmi	Jadon
	Catherine	Brookman		Catherine	Jephcott
	lan	Buley		Natalie	Jones
	Shelley	Chamberlain		Hannah	Loveday
	Stacey	Davies		Jane	Macdonald
	Angela	Foulds		Betania	Mahler-Araujo
	Meadow	Fisher-Crisp		Debra	Mansergh
	Joanne	Garfield-Smith		Ultan	McDermott
	Petra	Gee		Lindsay	Piper
	Caera	Good		Amy	Strong
	Hannah	Griffin		Catherine	Thorbinson
	Andrew	Harford-Brown		Saji	Victor
	Prithvi	Jampana		Naval	Vyse
	Ingrid	Koehler		Amanda	Walker
	Tyler	Lowe		Emma	Wong
	Sally	Maddison		Zsuzsa	Zaborszky
	Mitchell	McMillan	Guy's Hospital	Paul	Ross (PI)
	Louise	Medley	(London)		
	Lyn	Micklewright		Samantha	Barrett
	Louise	Paatz		Eva	Batovska
	Maeve	Pomeroy		Jessica	Brady
	Helen	Randall		Maribel	Воусе
	Fleur	Rogers		Laura	Camburn
	Lorraine	Thornton		Lorna	Caplis
	Christine	Tsang		Noan Minh	Chall
	Elaine	Vandecandalaere		Jason	Chow
	Sarah	Wright		Chi Yee	Chung
Addenbrooke's	Hugo	Ford (PI)		Sophie	Clark
Hospital				Sarah	Cleary
	Athar	Ahmad		Victoria	Donovan
	Alexandra	Azevedo		Sandra	Esteban Moreno
	Lesley	Bennett		Adrienn	Fazekasne Fulep
	Elizabeth	Blake		Lucy	Featherstone
	Mark	Bolton		Michael	Flanagan
	Rebecca	Bradley		Laura	Green
	Jane	Bushen		Sara	Hulf
	Joanna	Calder		Arun	Karnad
	Anita	Chhabra		Sara	Kazemzadeh
	Kathy	Chin		Vevangaune	Ketjiperue
	Sarah	Clark		Choi Chin	Lau
	Joseph	Gallagher		Nick	Maisey

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (princip investigator [PI]
	Simranjit	Mehta		Ravi	Kodavatiganti
	Ngozi	Muoneke		Arwel	Lloyd
	Theodorah	Nago		Bethan Wyn	Owen
	Rita	Njoku		Beryl	Roberts
	Vitalis	Nwokorie		Charley-Anne	Rutter
	Temi	Olusi		Jane	Stockport
	Kishen	Patel		Gemma	Szabo
	Amy	Quinn		lan	Walker
	Catherine	Rogers		Claire	Watkins
	Hannah	Rush		Glesni	Williams
	Susie	Slater		Linzi	Williams
	Anita	Soma	Glan Clwyd Hospital	Simon	Gollins (PI)
	Chara	Stavraka		Elizabeth	Allan
	Harriet	Waine		Jill	Andrews
	Sally	Walker		Kelly	Andrews
St George's Hospital	Fiona	Lofts (PI)		Lisa	Ashley
(London)				Llinos	Davies
	Doraid	Alrifa		Rachel	Davies
	Nia	Alsamarrai		Clair	Domeney
	Jason	Chow		Sarah	Evans
	Alice	Dainty		Emma	Hall
	Lorette	Ffolkes		Jane	Heron
	Caroline	Finlayson		Ravi	Kodavatiganti
	Claire	Gilmartin		Joanne	Lewis
	Anne	Haldeos		Arwel	Lloyd
	Sam	Hollingworth		Carey	Macdonald-Smith
	Geoffrey	Howell		Claire	McGregor
	Robert	Ingham		Bethan Wyn	Owen
	Kay	Laurent		Tracy	Parry-Jones
	Vitalis	Nwokorie		Fiona	Redmond
	Antonio	Pesino		Beryl	Roberts
	Mark	Quarrell		Charley-Anne	Rutter
	Agne	Sekmokaite		Libby	Thackray
	Jesusa	Toledo		lan	Walker
Wrexham Maelor	Simon	Gollins (PI)		Jill	Westlake-Guy
Hospital				Linzi	Westlake-Ouy Williams
	Stacy	Ackerley		Stephanie	Wynne
	Ashraf	Alkhaldi	James Cook University	Nick	Wadd (PI)
	Kelly	Andrews	Hospital	NICK	
	Rachel	Davies		Andrea	Воусе
	Alistair	Ellis-Jones		Alison	Chilvers
	Emma	Hall		Anthony	Donnelly
	Rachel	Hughes	(conti	nued on following	nage)

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Helen	Dunn		Nigel	Bailey
	Vicky	Hanlon		Thea	Barlow
	Charlotte	Jacobs		Kayleigh	Bennett
	Steven	Liggett		Carolyn	Brode
	Craig	Mower		Thomas	Cornell
	Lisa	Peacock		Alexander	Dengler
	Jacqueline	Richards		Emma	Duley
	Agnieszka	Skotnicka		Sophia	Eloi
	Danielle	Sweeney		Caroline	Goddard
	Jane	Thompson		Aaron	Gould
	Hans	Van der Voet		Anne	Griffiths
	Gill	Wheater		Karina	Harris
	David	Wilson		Peter	Helliwell
	Jason	Wong		Claire	Hill
Poole Hospital	Amelie	Harle (PI)		Louise	Johns
	Tamas	Hickish (PI)		Tinnaya	King
	Michael	Adrio		Samantha	Lomax
	Maria	Alban		Kirsty	Maclean
	Julian	Alexander		John	Madine
	Lyn	Allen		Joe	Mathew
	Mary	Apps		John	McGrane
	Beth	Aubrey		Fiona	Minear
	Helen	Bradley		Sharon	Moore
	Savina	Elitova		Anna	Oakes
	Daniel	Fielding		Caroline	Parnell
	Maxine	Flubacher		Kerena	Partridge
	Deborah	Forster		Sallyanne	Platt
	Melanie	Foster		Kirsty	Prout
	Louise	Heckford		William	Pynsent
	Jill	Hobson		Rebecca	Rogers
	Hannah	James		Jenifer	Row
	Min Yee	Lee		Laura	Royle
	Helen	Morling		Johanna	Skewes
	Victoria	Osborne		David	Smith
	Sharon	Power		Darren	Snell
	Victoria	True		Luke	Townley
	Craig	Vincent	Royal Free Hospital	Daniel	Krell (PI)
	Roger	Wheelwright		Astrid	Mayer (PI)
Royal Cornwall Hospita	I Richard	Ellis (PI)		Tahmin	Ahmed
	Linda	Allsop		lan	Clark
	Nicholas	Ashley		Jen	Fraser-Fish
	Kerry	Atkinson		Roopinder	Gillmore
(co	ntinued in next co	lumn)	(cor	tinued on following	g page)

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Sara	Hamilton		Karen	Flynn
	Ben	Marks		Michelle	Kotze
	Leah	Meaden		Michaela	Nock
	Aarti	Nandani		Jess	Perry
	Tesha	Suddason		Lucy	Pippard
	Sharon	Thompson		Kerry	Rennie
	Elizabeth	Woodford		Amber	Rowsell
South Tyneside District Hospital	Ashraf	Azzabi (PI)		Rufus	Smith
	Amy	Burns		Lesley	Thomas
	Kumud	Jain	Lincolo Count d locaital	Barbara	Williams-Yesson
	Judith	Moore	Lincoln County Hospital	Zuzana	Stokes (PI)
	Ruth	Tindle		Antoinette	Adu
St Bartholomew's	David	Propper (PI)		Suzanne	Archer
Hospital (London)				Sarah	Bell
	Waheeda	Abida		Jayne	Borley
	Hayley	Blackgrove		Sarah	Coombs
	Joanne	Chin-Aleong		Olesya	Francis
	Nikolaos	Diamantis		Annette	Hilldrith
	Resmi	Jayachandran		Kathryn	Hoare
	Sumaiya	Kamora		Carol	Lockwood
	Cheryl	Lawrence		Maryanne	Okubanjo
	Alia	Mahboob		Rhiannan	Pegg
	Juan	Navarro		Manuel	Ruiz-Echarri
	Tanjil	Nawaz		Thomas	Sheehan
	Pratistha	Panday		Anuradha	Sheth
	Hannah	Payne		Andrew	Sloan
	Stephen	Russell		Caroline	Taylor
	Sarah	Slater		Ruth	Thoy
eovil District Hospital	Andrew	Allison (PI)		Alyson	Wilson
	Erica	Beaumont (PI)	Maidstone Hospital	Mark	Hill (PI)
	Matthew	Sephton (PI)		Doraid	Alrifa
	Joanna	Allison		Elizabeth	Angus
	Zenaida	Armstrong		Paulette	Basham
	Claire	Barron		Lisa	Brown
	Nigel	Beer		Tracey	Chambers
	Kate	Beesley		Alison	Davison
	Edwin	Cooper		Jackie	Evans
	Sarah	De Bruijn		Sanjina	Kathuria
	David	Donaldson		Samantha	Kestenbaum
	Tracey	Duckett		Tiana	Kordbacheh
	Adam	Edwards		Satish	Kumar
		Fox		Barbara	LeBrocq
	Shirley itinued in next co		(conti	nued on following	g page)

Registered With All Staff Listed (N = 2,076) (continued)

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2.076) (continued)

lospital	First Name	Surname (principal investigator [PI])
	Gemma	McCormick
	Christos	Mikropoulos
	lan	Pamphlett
	Joanne	Patterson
	Caroline	Rodger
	Holly	Slater
	Charlotte	Stevens
	Jeff	Summers
	Alicia	Synowiec
	Katy	Taylor
	Lisa	Tribe
lottingham University Hospitals	Cristina	Lopez Escola (PI)
	Rebecca	Ashton
	Suha	Atabani
	Alex	Blades
	Emma	Blades
	Lauren	Blackburn
	Pauline	Brookes
	Eliot	Chadwick
	Caroline	Coulson
	Michelle	Cunnell
	James	Donworth
	Jade	Eggleton
	Susan	Elliott
	Joanne	Hobbs
	Shaymaa	Hosni
	Laura	Kirk
	Emma	Marshall
	Balwir	Matharoo-Ball
	Kayleigh	Mills
	Jamie	Mills
	Jeanette	Mulhurn
	Karen	Newcombe
	Vanessa	Potter
	Tin	Sang-Tsang
	Rosalind	Roberts
	Maria	Scott
	Rafael	Silverman
	Ananth	Sivanandan
	Tania	Slater
	Anita	Stevenson

Hospital	First Name	Surname (principa investigator [PI])
	Richard	Swinden
	Jackie	Worville
	Georgina	Walker
	Andrew	Wright
Hinchingbrooke Hospital	Cheryl	Palmer (PI)
	Shilamba	Bramham
	Sue	Donnelly
	Simon	Duke
	Vanessa	Goss
	Beverley	Haynes
	Rebecca	Lam
	Elizabeth	Lee
	Sarah	Littlechild
	Adam	McGeoch
	Suzanne	Miller
	Agnieska	Osmanska
North Middlesex Hospital	John	Bridgewater (PI)
	Ernesto	Balaguer-Ruiz
	Girish	Bhome
	Moira	Durdy
	Lorraine	Hurl
	Shardul	Kulkarni
	Simranjit Kaur	Mehta
	Lucinda	Melcher
	Julia	Rees
	Jamila	Roehrig
	Rahi	Shah
	Chloe	Van Someren
Queen Alexandra Hospital	Ann	O'Callaghan (PI)
	Oluwatobi	Adeagbo
	Suhail	Baluch
	Kathy	Blight
	Sherilee	Cook
	Heather	Cuell
	Tracey	Dobson
	Муа	Gyi
	Antony	Higginson
	Samuel Luke	Hill
	Chloe	Holden
	Tracey	Lee
(cc	ntinued on following	g page)

© 2021 by American Society of Clinical Oncology

Volume 39, Issue 33

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])
	Jayne	McCartney
	Badrriyya	Mohamedali
	Sethupathi	Muthuramalingam
	Andras	Nagy
	Eleanor	Taylor
	Mary	Wands
	Robert	Williams
	Carole	Wragg
Weston General Hospital	Stephen	Falk (PI)
	Paola	Di Nardo (PI)
	Marjorie	Tomlinson
	Kathy	Beard
	Sandra	Beech
	Hannah	Berry
	Debbie	Coles
	Donna	Cotterill
	Harvey	Dymond
	Symeon	Eleftheriadis
	Rajesh	Gamare
	Christine	Graham
	Serena	Hilman
	Sarah	Kidd
	Denise	Leighton-Price
	Hugh	Lloyd-Jones
	Andrew	McKendrick
	Kathryn	Munday
	Vivienne	Pixton
	Glenn	Saunders
	Ed	Sheffield
	Dawn	Simmons
	Axel	Walther
	Rachel	Warinton
	Tom	Wells
Glangwili General	Mau-Don	Phan (PI)
	Samantha	Coetzee
	Sonya	Goriah
	Praba	Gupta
	Ann	Hewins
	John	Murphy
	Zohra	Omar
	Bryan	Phillips
	continued in next c	

	investigator [PI])
Meena	Raj
Kelly	Reed
Rocio	Riba
Francisca Marti	Marti (PI)
Elena	Takeuchi (PI)
Jennifer	Cannon
Kate	Chilman
Shien	Chow
Louise	Devereaux
Alison	Doran
Diane	Forrest
Karen	Moss
Monica	Patel
Angela	Power
Wendy	Stevens
Ashraf	Azzabi (PI)
Hayley	Anderson
Rod	Beard
Jane	Cole
Michelle	Edwards
Adam	Hassani
James	Henry
Vivienne	Hullock
Stephen	Laybourne
Paula	Newton
Rachel	Pearson
lan	Pedley
lan	Pepley
Melanie	Robertson
Fiona	Wakinshaw
Kathryn	Wright
Charlotte	Rees (PI)
Louise	Beattie
Victoria	Corner
Abigail	Edwards
Adrienn	Fazekasne Fulep
Angela	Frith
Julie	Gwilt
Liz	Happle
Roger	Hudson
	Kelly Kelly Rocio Francisca Martia Jennifer Jennifer Kate Shien Louise Alison Diane Karen Monica Angela Vendy Ashraf Jane Jane Jane Kodu Jane Vivienne Stephen Paula Rachel Ian Ian Kathryn Charlotte Victoria Abigail Angela

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Registered With All Staff	Listed ($N = 2,07$	Surname (principal	Registe
Hospital	First Name	investigator [PI])	Hospi
	Andrew	Jackson	
	Lauriane	Kernwood	
	Lauriane	Kerwood	
	Kathryn	Leach	Queer
	Emma	Magras	Hos (Bir
	Asmat	Mustajab	(DII
	Christina	Narh	
	Pennie	Porter	
	Arun	Selvaraju	
	Jackie	Smith	
	Claire	Williams	-
Forth Valley Royal Hospital	Dawn	Storey (PI)	
	Joanne	Blackburn	
	Stephanie	Brogan	
	Raj	Burgul	
	Eilidh	Henderson	
	Jane	Keddie	
	Linnet	McGeever	Queer Bur
	Kaye	McIlvar	Bui
	David	McIntosh	
	Caroline	Mcleary	
	Lynn	Prentice	
	Annette	Riley	
	Joanne	Robinson	
	Anne	Todd	
	Patricia	Turner	
	Sally	Young	·
Mount Vernon Hospital	Mark	Harrison (PI)	·
	Farhan	Ahmed	·
	Nicola	Anyamene	·
	Nicky	Barnes	·
	Neel	Bhuva	·
	Sam	Bosompem	·
	Kari	Evans	D
	Shiv	Gayadeen	Russe
	Rob	Glynne-Jones	-
	Marcia	Hall	
	Rakhi	Jain	
	Colleen	Murray	
	Julie	Russell	
	Waqar	Saleem	
(000	tinued in next col		

Hospital	First Name	Surname (principa investigator [PI])
	Anand	Sharma
	Margaret	Stone
	Harsha	Vara
Queen Elizabeth Hospital (Birmingham)	Gary	Middleton (PI)
	Sabia	Akhtar
	Amisha	Desai
	Colm	Forde
	Kam	Gareja
	Sharon	Hackett
	Sam	Hopkins (nee Poole)
	Mary	Kotadia
	Victoria	Kunene
	Catherine	Prest
	Helen	Preston
	Donna	Smith
	Phillipe	Taniere
Queen's Hospital Burton	Manjusha	Keni (PI)
	Ann	Adams
	Mosan	Ashraf
	Jo	Burns
	Helen	Cox
	Katy	English
	Annette	Fleet
	Sarah	Hathaway-Lees
	Elizabeth	Kemp
	Hayley	Lewis
	Clare	Mewies
	Jennifer	Moyes
	James	Price
	Scott	Sanders
	Adrian	Smith
	Alison	Tilley
Russells Hall Hospital	Ankit	Jain (PI)
	Simon	Grumett (PI)
	Joann	Atkinson
	Daniel	Bull
	Donna	Cleal
	Lesley	Edwards
	Kath	Harrow
	Stacey	Jennings

© 2021 by American Society of Clinical Oncology

Volume 39, Issue 33

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principa investigator [PI])
	Lucy	Kadiki		Yasmin	Brough
	Karen	Kanyi		Maggie	Brown
	Sally	Keates-Porter		Dannielle	Burgess
	Pek	Keng-Koh		Luanne	Carey
	Margaret	Marriott		Philippa	Clark
	Julie	Matthews		Peter	Correa
	Karen	McGarry		Kishore	Gopalakrishnan
	Vanessa	Moore		Cheryl	Hunter
	Andrew	Moores		Sian	Kempster
	Manesh	Patel		Mohammed	Khan
	Veena	Shinde		Fiona	McGurk
	Lucie	Smith		Jade	McKelvie
	Lucy	Smith		Lucy	Miller
	Angela	Watts		Sarah	O'Toole
Singleton Hospital	Sarah	Gwynne (PI)		Karandeepu	Pachoo
	Cristina	Lopez (PI)		Noor	Shaw
	Alya	Al-Affan		Laura	Stanley
	Philip	Bryant		Charlie-marie	Suddens
	Karen	Chesters		Rachel	Thompson
	Sharon	Davies		Maria	Truslove
	Jenna	Edwards		Linda	Wimbush
	Stuart	Evans		Jane	Wording
	Tracey	Ford	University Hospital of	Madhavi	Adusumalli (PI)
	Ricky	Frazer	North Tees		
	Judith	Gooding		David	Wilson (PI)
	Olivia	Hatcher		Alison	Chilvers
	Gillian	Jones		Helen	Dunn
	Lewis	Jones		Sarah	Essex
	Maung	Мое		Mohammad	Hegab
	Karen	Phillips		Hyder	Latif
	Euan	Pratt		Moira	Percival
	Alex	Richards		Sarah	Pitcairn
	Louise	Thomas		Lynda	Poole
	Julie	Turner		Pam	Race
	Nia	Viney		Andrew	Sigsworth
	Dawn	Withers		Eleni Andriana	Trigka
University Hospital	Vanessa	Potter (PI)		Helen	Wardle
Coventry				Bill	Wetherill
	Jason	Allen	Whittington Hospital	Pauline	Leonard (PI)
	Senthil Kumar	Athmanathan	(London)	Dealett	0.1
	Rachel	Bazeley		Rashidat	Adeniba
	Susan	Bird		Dhili	Arul
(c	ontinued in next col	umn)		Jonathan tinued on following	Flor

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])
	Kavita	Kantilal
	Xiao Lou	Lu
	Mulyati	Mohamed
	Michelle	Saull
	Nuray	Temiz
	Azmina	Verjee
	Simon	Wan
Freeman Hospital, Newcastle	Ashraf	Azzabi (PI)
	Craig	Alderson
	Chris	Barron
	Michelle	Borthwick
	Julie	Burton
	Kay	Carson
	Fiona	Chapman
	Sarah	Cook
	Fareeda	Coxon
	Sue	Farrell
	Elaine	Greaves
	Ahmed	Hashmi
	Amanda	Henderson
	Kathryn	Hewitt
	Ben	Hood
	Thomas	Jarvis
	Irene	Jobson
	Najibah	Mahtab
	Lesley	Naik
	Stephanie	Needham
	Gemma	O'Neill
	lan	Pedley
	Sindhu	Ramamurthy
	Zarine	Razvi
	Elizabeth	Reay
	Timothy	Simmons
	Carole	Stobbart
	Jonathan	Stoddart
	Nichola	Waugh
	Hesther	Wilson
Leighton Hospital	Michael	Braun (PI)
<u> </u>	Vanessa	Adamson
	Carole	Bennion
	Kim	Best
	ontinued in next co	

Hospital	First Name	Surname (principal investigator [PI])
	Leanne	Everall
	Julia	Gemmell
	Laura	Hanton
	Christy	Henderson
	Adele	Hough
	Chris	Hough
	Cyndy	Jackson
	Тауа	Jones
	Tracy	Larcombe
	Carolyn	Mansfield
	Emma	Margerum
	Julie	Meir
	Andrew	Ritchings
	Paul	Simcock
	Sarah	Tinsley
	Caroline	Walker
Ninewells Hospital, Dundee	Sharon	Armstrong (PI)
	Jennifer	Allison
	Rachael	Banks
	Anne	Black
	Louise	Brannan
	Frank	Carey
	Shona	Carson
	Helen	Cumming
	Debbie	Forbes
	Audrey	Lyall
	AJ	Munro
	Moira	Rogers
	lan	Sanders
	Gail	Weir
Westmorland General Hospital	David	Eaton (PI)
	Rebecca	Anderson
	Syed	Asghar
	Manal	Atwan
	Claire	Bartlett
	Ashoke	Biswas
	Jennifer	Bowler
	Karen	Burns
	Rebecca	Calvert
	Amy	Ford
	Laura	Healey
(cont	inued on following	

© 2021 by American Society of Clinical Oncology

Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])	Hospital	First Name	Surname (principal investigator [PI])
	Nima	Herlekar	Great Western Hospital	Sarah	Lowndes (PI)
	Maria	Kassi		Graham	Brown
	Lauren	Kilifin		Christopher	Clarke
	Jo	Kilkenny		Amanda	Colston
	Nicola	Mackenzie		Jan	Dodge
	Aileen	Menzies		Eva	Fraile
	Helen	Morris		Sarah	Grayland
	Debbie	Power		Lesley	Haxton
	Jane	Ritchie		Lawrence	John
	Mary	Robinson		Jean	Kordula
	Vickie	Rose		Lynsey	Kyeremeh
	Rachel	Simmons		Donna	Lake
	Andrew	Taylor		Catherine	Lewis Clarke
	Hilary	Thatcher		Sarah	Long
	Gail	Wiley		Dorota	Marciniak
Belfast City Hospital	Victoria	Coyle (PI)		Laura	McCafferty
	Conal	Askin		Darren	McFadden
	Ellen	Brown		Sue	Meakin
	Karen	Campfield		Chanelle	Meyer
	Catherine	Davidson		Tim	Owen
	Michael	Hanna		Cerila	Parajes
	Diane	Law		Ronak	Patel
	Alison	McKeever		Suzannah	Pegler
	Aine	McKeown		Caroline	Pensotti
	Damian	McManus		Joseph	Stevens
	Linda	McNeice	Milton Keynes	Wasiru	Saka (PI)
	Karen	Parsons	University Hospital		
	Miranda	Reid		Ann	Abraham
	Fiona	Tarpey		Hannah	Ansell
	Joanne	Todd		Sam	Bosompem
	Paul	Ward		Matthew	Burnett
	Richard	Wilson		Chris	Ford
Dorset County Hospital	Amelie	Harle (PI)		Chloe	Green
	Richard	Osborne (PI)		Sara	Greig
	Pauline	Ashcroft		Penni	Hawkins
	Corrado	d'Arrigo		Chamene	Hicks
	Maxine	Flubacher		Aarzoo	Ilyas
	Jackie	Gibbins		Charity	Masvaure
	Karen	Hogben		Louise	Moran
	Arabis	Oglesby		Mala	Nathvani
	Andrew	Rees		Cheryl	Padilla-Harris
	Simon	Wilsher		Vijay	Patel
(con	tinued in next co		(conti	nued on following	g page)

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

Registered With All Staff Listed (N = 2,076) (continued)

Hospital	First Name	Surname (principal investigator [PI])
	Shahriar Mohammed	Reza
	Syed Azhar Javed	Rizvi
	Abby	Skillington
	Jeannette	Smith
	Oliver	Spring
	Heather	Thomas
	Stephanie	Thorp
	Valerie	Webb
	Dona	Wingfield
	Christopher	Woodard
New Cross Hospital	Simon	Grumett (PI)
	Syed	Asghar
	Vanda	Carter
	Sandeep	Dhillon
	Anna	Grant
	Clare	Hammond
	Kelly	Kauldhar
	Margaret	King
	Christine	Kirk
	Claire	Lomas
	Manel	Mangalika
	Gurminder	Sahota
	Elaine	Wylde
Pilgrim Hospital	Zuzana	Stokes (PI)
	Antoinette	Adu
	Simon	Archer
	Gloria	Barone
	Jayne	Borley
	Wendy	Deamer
	Jo	Fletcher
	Matthew	Flook
	Amy	Kirkby
	Victoria	Knight
	Tara	Lawrence
	Beverley	Mashegede
	Helen	Palmer
	Kerry	Pettitt
	Gunjan	Phalod
	Manuel	Ruiz-Echarri
	Gemma	Sankey
	Thomas	Sheehan
(cc	ntinued in next col	umn)

Hospital	First Name	Surname (principal investigator [PI])
	Rebecca	Spencer
	Kinga	Szymiczek
	Isobel	Thomas
Rotherham District General Hospital	Joanne	Hornbuckle (PI)
	Matthew	Barnes
	Sarah	Besley
	Meredyth	Harris
	Kath	Lowe
	Scott	Nicol
	Susan	Oakley
	Amy	Rees
	Charlotte	Widdop
Royal Bournemouth Hospital	Tamas	Hickish (PI)
	Jocelyn	Ablorde
	Omolade	Bakarey
	Rachel	Bower
	Zoe	Clark
	Nicole	Davies
	Alison	Hogan
	Stephanie	Jones
	Tiffany	Joyce
	Maria	Lane
	Sharon	Megson
	Sandy	Pressdee
	Linda	Purandare
	Taslima	Rabbi
	Emma	Sharland
	Esther	Una Cidon
	Luke	Vamplew
	Jasmin	Webb
Royal Marsden Hospital (London)	lan	Chau (PI)
	Helen	Breeze
	Shirley	Clifton
	Saoirse	Dolly
	Sandra	Esteban Moreno
	Lucy	Featherstone
	Shelby	Hatt
	Blanka	Hezelova
	Alexander	Lee
	Hazel	Lote

© 2021 by American Society of Clinical Oncology

Volume 39, Issue 33

Participating Hospitals in Descending Order of the Number of Patients Participating Hospitals in Descending Order of the Number of Patients Registered With All Staff Listed (N = 2,076) (continued)

ospital	First Name	Surname (principa investigator [PI])
	Lizzie	Love
	Nnenna	Ngwu
	Isma	Rana
	Gihan	Ratnayake
	Penny	Rogers
	Clare	Saffery
	Anna	Scott
	Izelle	Ueckermann
	Chloe	Westrip
	lan	Chau
	Sally	Abdelmalik
	Gayahri	Anandappa
	Joo Ern	Ang
	Thushasa	Ansari
	Sheila	Azaiji-Benjamin
	Annette	Bryant
	Shirley	Clifton
	Richard	Crux
	David	Cunningham
	Sara	Diffley
	Julie	Duncan
	Laurice	Edwards
	Sandra	Esteban Moreno
	Lucy	Featherstone
	Monika	Ferencova
	Angela	Gillbanks
	Sarnjeet	Kaur
	Naila	Kaudeer
	Shelize	Khakoo
	Shannon	Kidd
	Retchel	Lazaro Alcausi
	Hazel	Lote
	Jacqueline	Oates
	Bijal	Patel
	Minal	Patel
	Brenda	Pem
	Sijy	Pillai
	Clare	Saffery
	Francesco	Sclafani
	• • • • •	Smith
	Gillian	SITIILIT

		Surname (principa		
Hospital	First Name	investigator [PI])		
	Jan	Thomas		
	Andrea	Turner		
	Izelle	Ueckermann		
	David	Watkins		

Adams et al




FIG A1. Swimmer plot for FOCUS4-N, by location of primary tumor. CT, computed tomography.

TABLE A1.	Baseline Characteristics of Laboratory Tests by Treatment Allocation for FOCUS4-N
	Active Menitering

	Active Mor	nitoring	Capecit	abine
		Mean (SD)		Mean (SD)
Characteristic	No.	Median (IQR)	No.	Median (IQR)
WBC, 10 ⁹ /L	127	6.3 (2.2)	127	6.6 (8.8)
		6.0 (4.6-7.4)		5.8 (4.9-7.6)
Neutrophils, 10 ⁹ /L	127	3.7 (1.8)	127	4.0 (3.4)
		3.4 (2.4-4.7)		3.5 (2.5-4.8)
Platelets, 10 ⁹ /L	127	244 (90)	127	249 (83)
		239 (190-284)		237 (184-294)
Serum bilirubin, mmol/L	127	8.7 (4.1)	127	8.3 (3.9)
		8.0 (6.0-11.0)		8.0 (5.0-10.0)
ALP, U/L	127	132 (79)	127	112 (60)
		110 (84-154)		98 (81-124)
AST/ALT, U/L	127	25.7 (14.5)	127	28.2 (17.5)
		22 (16-31)		24 (17-34)
Renal function, mL/min	126	90.5 (28.6)	127	90.5 (27.3)
		90 (69-100)		90 (71-101)
CEA, µg/L	122	96 (427)	125	83 (251)
		6 (3-28)		8 (3-22)
LDH, U/L	115	369 (149)	114	429 (489)
		353 (241-464)		376 (254-454)

Abbreviations: ALP, alkaline phosphatase; CEA, carcino embryonic antigen; IQR, interquartile range; LDH, lactate dehydrogenase; SD, standard deviation.

 TABLE A2.
 Worst Toxicity Reported per Patient, by the Treatment Arm
 TABLE A2.
 Worst Toxicity Reported per Patient, by the Treatment Arm

 in FOCUS4-N

in FOCUS4-N (continued)

	nt Arm	
CTC Grade	Active Monitoring, No. (%) $(n = 127)$	Capecitabine, No. (%) $(n = 127)$
Nausea		
0	94 (74)	85 (67)
1	15 (12)	27 (21)
2	10 (8)	10 (8)
3	1 (1)	1 (1)
Missing	7 (6)	4 (3)
Vomiting		
0	106 (83)	108 (85)
1	7 (6)	9 (7)
2	6 (5)	5 (4)
3	1 (1)	1 (1)
Missing	7 (6)	4 (3)
Diarrhea		
0	92 (72)	58 (46)
1	19 (15)	40 (31)
2	6 (5)	19 (15)
3	3 (2)	6 (5)
Missing	7 (6)	4 (3)
Stomatitis		
0	114 (90)	98 (77)
1	5 (4)	21 (17)
2	1 (1)	4 (3)
Missing	7 (6)	4 (3)
Dry skin		
0	105 (83)	81 (64)
1	14 (11)	38 (30)
2	1 (1)	3 (2)
3	0 (0)	1 (1)
Missing	7 (6)	4 (3)
Skin rash		
0	111 (87)	104 (82)
1	9 (7)	14 (11)
2	0 (0)	3 (2)
3	0 (0)	2 (2)
Missing	7 (6)	4 (3)
Nail dystrophy		
0	110 (87)	105 (83)
1	9 (7)	16 (13)
2	1 (1)	2 (2)
Missing	7 (6)	4 (3)
	(continued in next colu	mn)

	Treatment Arm			
CTC Grade	Active Monitoring, No. (%) $(n = 127)$	Capecitabine, No. (%) $(n = 127)$		
PPE				
0	111 (87)	56 (44)		
1	5 (4)	35 (28)		
2	4 (3)	25 (20)		
3	0 (0)	7 (6)		
Missing	7 (6)	4 (3)		
Anemia				
0	88 (69)	69 (54)		
1	20 (16)	43 (34)		
2	11 (9)	9 (7)		
3	1 (1)	3 (2)		
Missing	7 (6)	3 (2)		
Neutropenia				
0	114 (90)	115 (91)		
1	3 (2)	4 (3)		
2	0 (0)	2 (2)		
3	0 (0)	2 (2)		
4	2 (2)	1 (1)		
Missing	8 (6)	3 (2)		
Total	127 (100)	127 (100)		

Abbreviation: PPE, palmar-plantar erythema.

© 2021 by American Society of Clinical Oncology